Effects of Serotonin and Noradrenaline on Neuroplasticity and Excitability of The Primary Motor Cortex in Humans by Kuo, Hsiao-I
 
 
Effects of Serotonin and Noradrenaline on 
Neuroplasticity and Excitability of The 






zur Erlangung des humanwissenschaftlichen Doktorgrades 
in der Medizin 
















Doctoral Thesis Committee 
 
 
Prof. Dr. Nitsche, Michael (Supervisor) 
Abteilung Klinische Neurophysiologie  
Universitätsmedizin Göttingen  
Robert-Koch-Straße 40  
37075 Göttingen 
 
Prof. Dr. Niklas, Andree (Thesis reviewer) 
Georg August University Göttingen  
Institut for sportmedizin  
Sprangerweg 2  
37075 Göttingen 
 
Prof. Dr. Blumentritt, Siegmar (Thesis reviewer) 
PFH Private Hochschule Goettingen 















Statement of Originality 
 
I hereby declare that this thesis “Effects of Serotonin and Noradrenaline on 
Neuroplasticity and Excitability of The Primary Motor Cortex in Humans” was 
independently written and with no other sources and aids than quoted in the text, 



















Table of Contents 
 
 
Chapter 1- Introduction .............................................................................................. 1 
1.1 Plasticity in the central nervous system ....................................................... 3 
1.1.1 Overview .............................................................................................. 3 
1.1.2 Neuroplasticity in humans ................................................................. 5 
1.1.3 Motor system as a model for neuroplasticity in humans................. 5 
1.2 Non-invasive brain stimulation in humans .................................................. 6 
1.2.1 Transcranial magnetic stimulation (TMS) ....................................... 6 
1.2.2 Transcranial direct current stimulation (tDCS) .............................. 8 
1.3 Pharmacological modulation of human cortical plasticity....................... 10 
1.3.1 Serotonergic modulation of plasticity ............................................. 11 
1.3.2 Noradrenergic modulation of plasticity .......................................... 12 
1.4 Acute vs. chronic application ...................................................................... 14 
1.5 Aims of the study .......................................................................................... 16 
Chapter 2- Original articles and manuscripts......................................................... 17 
2.1 Chronic enhancement of serotonin facilitates excitatory transcranial 
direct current stimulation-induced neuroplasticity ........................................ 18 
2.2 Acute and chronic effects of noradrenergic enhancement on transcranial 
direct current stimulation (tDCS)-induced neuroplasticity in humans ........ 28 
2.3 Acute and chronic noradrenergic effects on cortical excitability in 
healthy humans .................................................................................................. 57 
Chapter 3- Summary ................................................................................................. 94 
3.1 General remarks .......................................................................................... 94 
3.2 Functional implications ............................................................................... 94 
3.3 Limitations .................................................................................................... 95 
3.4 Future perspectives ...................................................................................... 96 
References ................................................................................................................... 99 
Acknowledgements .................................................................................................. 107 




Chapter 1- Introduction 
 
Neuroplasticity is the capacity of neural activity generated by an experience to 
modify neural circuit function and thereby modify subsequent thoughts, feelings, and 
behaviors (Criti & Malenka, 2008). The best explored forms of plasticity are 
long-term potentiation (LTP) and long-term depression (LTD), that is, the 
strengthening or weakening of excitatory (or inhibitory) synapses (Criti & Malenka, 
2008). Recently, abnormal neuroplasticity has come increasingly into the focus as a 
correlate and pathological mechanism in many neurological and psychiatric diseases 
(e.g., stroke, Alzheimer’s disease, Parkinson’s disease, and depression) (Cooke & 
Bliss, 2006). Therefore, modification of such pathological plasticity, or enhancing 
beneficial plasticity in these diseases, might be an interesting new therapeutic option 
(Kuo et al., 2014).  
At the cellular level, plasticity is induced predominantly at glutamatergic and 
GABAergic synapses. The respective plasticity can however be altered by so-called 
neuromodulators, such as dopamine (DA), acetylcoline (Ach), serotonin (5-HT), and 
noradrenaline (NE) (Gu, 2002). These effects have so far been mainly studied in 
animal models. Typically, the role of neuromodulators in synaptic changes critically 
depends on the receptor subtypes, the concentration and kind of activity of the 
modulators, and their site of action. Among these neuromodulators, serotonin and 
noradrenaline received more attention recently since both of them are involved in 
diverse brain functions and also play important role in different psychiatric diseases 
(Ohashi et al., 2003; Straube & Frey, 2003).  A number of studies have shown that 
serotonin can enhance LTP (Kojic et al., 1997; Park et al., 2012) and block LTD 
(Normann et al., 2007). Activation of 5-HT receptors was further shown to convert 
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LTD induction into LTP (Kemp & Manahan-Vaughan, 2005). Furthermore, 
application of a selective serotonin reuptake inhibitor (SSRI) led to significantly 
enhanced LTP in the rat hippocampus, but the effect was present only after repeated 
application (Kemp & Manahan-Vaughan, 2005). With regard to the noradrenergic 
system, noradrenaline has shown to facilitate LTP and block LTD (Katsuki et al., 
1997; Hu et al., 2007). In addition, chronic administration of the selective 
noradrenaline reuptake inhibitor (NRI) reboxetine (RBX) restored spatial learning 
deficits and hippocampal synaptic plasticity in an animal model of depression 
(Bhagya et al., 2015). 
Recently developed noninvasive brain stimulation protocols provide the 
opportunity to study LTP/LTD-like plasticity at the system level of the human brain 
(Cooke & Bliss, 2006; Ziemann et al., 2008). Transcranial direct current stimulation 
(tDCS) is one of these stimulation protocols. It induces prolonged excitability changes 
in humans: Anodal stimulation increases and cathodal stimulation decreases cortical 
excitability (Nitsche & Paulus, 2001; Nitsche et al., 2003a). Its primary mechanism of 
action is neural hyperpolarization accomplished by cathodal tDCS and subthreshold 
neural depolarization induced by anodal tDCS. Neuroplastic aftereffects are 
N-methyl-D-asparate (NMDA) and Ca2+ -dependent and affected by 
neuromodulators, such as dopamine, acetylcholine, serotonin, and noradrenaline 
(Nitsche et al., 2003b; Nitsche et al., 2004; Kuo et al., 2007; Nitsche et al., 2009). 
Previous studies have found that dopaminergic and cholinergic activation affects 
plasticity in humans, which depends on dosage, the plasticity induction protocol, and 
the subtype of receptors (Nitsche et al., 2012).  
The effects of serotonin and noradrenaline on plasticity in humans were explored in 
two recent experiments. A single dose of the SSRI citalopram enhanced both the 
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amplitude and duration of the after effect of anodal tDCS, whereas it reversed the 
inhibition seen after cathodal tDCS to facilitation (Nitsche et al., 2009). Regarding 
noradrenaline, the monoamine reuptake inhibitor amphetamine enhanced duration of 
facilitation induced by anodal tDCS (Nitsche et al., 2004). In addition, previous 
studies suggested that acute application of selective NRI enhances cortical excitability 
in the human brain (Herwig et al., 2002). These results give us an initial insight how 
serotonin and noradrenaline affect neuroplasticity and cortical excitability in the 
human brain. Interestingly, clinical studies showed that it usually takes several weeks 
to obtain therapeutic effects of serotonergic and noradrenergic agents 
(Bezchilbnyk-Butler et al., 2000; Kasper et al., 2000). However, knowledge about the 
impact of chronic serotonergic and noradrenergic enhancement in humans on 
plasticity and excitability is limited at present.  
In this project, we were interested to explore the impact of acute and chronic 
serotonergic and noradrenergic receptor activity enhancement on functional plasticity 
of the human brain. Furthermore, we investigated the acute and chronic effects of 
noradrenaline on cortical excitability in humans. The first chapter introduces basic 
mechanisms relevant for understanding the studies included in the thesis. The second 
chapter consists of the papers presenting the research results. The concluding chapter 
summarizes the main results of the studies and offers an outlook to future research in 
the field. 
 
1.1 Plasticity in the central nervous system 
 
1.1.1 Overview 
One of the most fascinating properties of the mammalian brain is its plasticity; the 
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ability of brain to reorganize its structure and function due to intrinsic or 
environmental demands (Criti & Malenka, 2008). At the cellular level, long term 
potentiation (LTP) and long term depression (LTD) are the most widely studied 
neuroplastic mechanisms considered to be fundamental for learning and memory 
formation (Rioult-Pedotti et al., 2000; Cooke & Bliss, 2006). These processes are 
most detailed studied at glutamatergic synapses, especially in the region of the 
hippocampus, but also in other cortical and subcortical areas (Malenka & Bear, 2004). 
Plasticity of the glutamatergic system is accomplished primarily via 
calcium-permeable N-methyl-D-asparate (NMDA) receptors (Cooke & Bliss, 2006). 
The induction of LTP is accomplished by activation of postsynaptic NMDA receptors 
and calcium-dependent protein kinases which results in the postsynaptic insertion of 
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors (Criti & 
Malenka, 2008). LTD is generated by moderate activation of NMDA receptors and 
another type of calcium-dependent enzymes which leads to the internalization of 
postsynaptic AMPA receptors (Criti & Malenka, 2008). It is well known that 
increased postsynaptic intracellular calcium concentration is an important signal for 
the induction of LTP and LTD (Gu, 2002; Malenka & Bear, 2004; Criti & Malenka, 
2008). High enhancement of intracellular calcium induces LTP, whereas low 
enhancement results in LTD (Lisman, 2001). The mechanisms of synaptic alteration 
are in accordance to the rules of Hebbian plasticity, characterized by longevity, input 
specificity and associativity, which state that learning and memory are based on 
modifications of synaptic strength among neurons (Martin et al., 2000).  Moreover, 
these mechanisms are important for adaptive reorganization of cortical networks of 





1.1.2 Neuroplasticity in humans 
Despite the findings in animal models, direct evidence in humans has shown that 
neuroplastic alterations play a crucial role in the cerebral cortex (Cooke & Bliss, 
2006). Studies demonstrated that neural activity in ipsilesional and contralesional 
cortical areas are pathologically changed (Aydina et al., 2007) following injury in 
stroke patients (Levy et al., 2001; Hodics et al., 2006). However, these changes are 
converted after rehabilitation, and correlated to functional recovery (Johansen-Berg et 
al., 2010). Apart from stroke, pathological alterations of plasticity are increasingly 
explored as relevant factors in diverse neurological and psychiatric diseases, such as 
Parkinson’s disease, Alzheimer disease and depression (Ueki et al., 2006; Normann et 
al., 2007). Not only in pathological states, but also in physiological conditions, such 
kinds of plasticity have been observed, for example in musicians (Pantev et al., 2001), 
mathematicians (Aydina et al., 2007), athletes (Park et al., 2009) and following motor 
practice (Ziemann et al., 2001). Therefore, exploring the mechanisms of 
neuroplasticity can improve our knowledge about fundamental mechanisms of brain 
physiology not only in health but also in disease. 
 
1.1.3 Motor system as a model for neuroplasticity in humans 
  In humans, cortical excitability alterations as a sign of LTP/LTD-like plasticity is 
typically monitored by the amplitude of the motor-evoked potential (MEP), which is 
elicited by transcranial magnetic stimulation (TMS) of the motor cortex. For 
obtaining MEPs, small hand muscles are most often used because of the superficial 
position of their motor cortex representation, low thresholds for stimulation and 
relatively large representations. In all studies mentioned in the thesis, MEPs have 
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been obtained from the abductor digiti minimi muscle (ADM). The MEP amplitude 
obtained by single pulse TMS is a measure of corticospinal excitability (Rothwell, 
1993) that reflects the synaptic strength and the balance of excitatory and inhibitory 
inputs at the synapses of corticospinal neurons (Ziemann, 2003).  
 
1.2 Non-invasive brain stimulation in humans 
Recently, a number of non-invasive brain stimulation tools applicable in humans 
became available such as TMS, repetitive transcranial magnetic stimulation (rTMS), 
transcranial direct current stimulation (tDCS), and paired associative stimulation 
(PAS), which can further increase our understanding of cortical plasticity via 
monitoring cortical excitability, or controlled induction of plasticity. With these 
techniques, it has become possible to evaluate and influence cortical activity in 
awake, behaving humans. Here, we introduce TMS and tDCS, which are related to 
our current studies.  
 
1.2.1 Transcranial magnetic stimulation (TMS) 
  TMS was introduced by Anthony Barker in 1985 (Barker et al., 1985). It is a safe 
and painless noninvasive brain stimulation technique to study neural activity in 
conscious humans (Kobayashi & Pascual-Leone, 2003; Wagner et al., 2007). TMS 
uses a rapidly changing magnetic field to elicit electric currents running parallel to the 
cortical surface via electromagnetic induction. These brief pulsed magnetic fields 
painlessly pass through the skull and can create electric currents of sufficient 
magnitude in discrete brain regions to depolarize neurons. TMS activates both 
excitatory and inhibitory neuronal elements in the cerebral cortex (Kobayashi & 
Pascual-Leone, 2003). Unlike electric stimulation, which excites cortical output 
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neurons directly (Merton & Morton, 1980), TMS is thought to stimulate these neurons 
indirectly via interneurons and can therefore elicit responses that reflect cortical 
excitability. The design of TMS consists of a main stimulator and a stimulating coil. 
In the studies discussed below, TMS is applied to the primary motor cortex (M1) for 
eliciting a response in the abductor digiti minimi (ADM) muscle. The resulting MEP 
is recorded via surface electromyography (EMG) (Rothwell, 1993). TMS can be 
delivered in the form of single, paired, and repetitive pulses; each of those protocols is 
applied for different purposes. In our studies, we applied single and paired pulse 
TMS, which we introduce in more detail below. 
 
1.2.1.1 Single-pulse TMS 
Single-pulse TMS provides information about corticospinal excitability by 
measuring variables such as motor thresholds (MTs) (including: active motor 
threshold (AMT), and resting motor threshold (RMT)), MEP amplitudes, and the 
input-output curve (I-O curve). MTs reflect neuronal membrane excitability and 
depend primarily on ion channel activity, as MTs are increased by voltage-gated 
sodium channel blockers, but not affected by drugs modulating gamma-aminobutyric 
acid (GABA)-ergic or glutamatergic transmission (Ziemann et al., 1996; Ziemann et 
al., 1998a). The I-O curve serves as an index of excitability of larger neuronal 
populations compared to MTs (Chen, 2000; Abbruzzese & Trompetto, 2002). The I-O 
curve depends on neuronal membrane excitability, because its slope is decreased by 
sodium and calcium channel blockers. Furthermore, synaptic mechanisms are 
involved, as it is modulated by drugs influencing the GABAergic and glutamatergic 
system, especially with higher stimulation intensities (Boroojerdi et al., 1999; Di 




1.2.1.2 Paired-pulse TMS 
  Paired-pulse is delivered at varying interstimulus intervals and stimulation 
intensities to elicit cortical inhibition or facilitation. Short-latency intracortical 
inhibition (SICI) and facilitation (ICF), motor cortex indirect waves (I-waves), and 
short-interval afferent inhibition (SAI) were monitored by paired-pulse TMS in our 
studies. For obtaining SICI-ICF, the subthreshold conditioning stimulus (determined 
as 70% of AMT) precedes the test stimulus. The test pulse was adjusted to achieve a 
baseline MEP of ~1mV and readjusted during the respective stimulation protocols, if 
needed, to compensate for effects of global excitability changes on test-pulse 
amplitude. SICI is mainly controlled by glutamate and GABAA receptors and based 
on induction of inhibitory postsynaptic potentials (Ziemann et al., 1996; Liepert et al., 
1997; Ziemann et al., 1998a). ICF is thought to reflect activity of GABAergic and 
predominantly glutamatergic systems (Ziemann, 2004). For I-wave facilitation, the 
TMS test stimulus precedes the conditioning stimulus (determined as 70 % of RMT). 
I-waves are thought to be primarily controlled by GABA-related neuronal circuits 
(Ziemann et al., 1998a; Ziemann et al., 1998b). SAI combines peripheral and motor 
cortex stimulation. In this protocol, a suprathreshold electric pulse (width of 200 μs 
and an intensity of 200% of the perceptual threshold) over the ulnar nerve precedes 
the motor cortex TMS test pulse. With SAI, it is possible to evaluate the cholinergic 
system in humans such as in patients with Alzheimer’s disease (Di Lazzaro et al., 
2006).  
 
1.2.2 Transcranial direct current stimulation (tDCS) 
  This non-invasive brain stimulation tool was established in the 1950s and 1960s 
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primarily in animals (Bindman et al., 1964b; Purpura & Mcmurtry, 1965). According 
to these early experiments, it was shown that subthreshold direct current stimulation 
increases spontaneous neuronal activity if the anode is placed over the cortex, while 
reversal of electrode polarity, i.e. positioning of the cathode over the motor cortex, 
resulted in reduced activity (Bindman et al., 1964a; Purpura & Mcmurtry, 1965). 
Later experiments revealed the excitability and activity changes can last for many 
hours after the end of stimulation for a few minutes, depend on protein synthesis 
(Gartside, 1968), intracellular cyclic adenosine monophosphate (cAMP) concentration 
(Hattori et al., 1990), and gene expression mediated by N-methyl-D-asparate 
(NMDA) receptors (Islam et al., 1995a; Islam et al., 1995b). Therefore, the 
after-effects depend on plasticity mechanism similar to those obtained in LTP and 
LTD induced by “classic” stimulation protocols (Islam et al., 1995a). 
For application in humans, Nitsche and Paulus developed non-invasive transcranial 
application of weak direct currents to the human motor cortex, termed transcranial 
direct current stimulation (tDCS) (Nitsche & Paulus, 2000, 2001). Anodal stimulation 
elicits neural depolarization which enhances cortical excitability, whereas cathodal 
tDCS results in neural hyperpolarization which diminishes cortical excitability 
(Nitsche & Paulus, 2001; Nitsche et al., 2003a). Stimulation for some minutes results 
in respective neuroplastic effects, which depend on glutamatergic mechanisms and are 
calcium-dependent (Nitsche and Paulus, 2000, 2001; Nitsche et al., 2003a; Nitsche et 
al., 2005). Nevertheless, tDCS-induced plasticity differs from classical plasticity 
induction protocols, used primarily in vitro. The latter involve not tonic subthreshold, 
but pulsatile suprathreshold stimulation. Thus, mechanisms of plasticity might not be 
identical, although similarities like NMDA receptor dependency, and calcium 
dependency, are present (Liebtanz et al., 2002; Nitsche et al., 2003b). 
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  TDCS consists of applying prolonged, low-intensity electrical currents over the 
scalp –usually delivered by a small battery-driven constant current stimulator- by 
attaching electrodes (sizes employed about 25-35 cm2) with different polarities to the 
skin (Brunoni et al., 2012). To stimulate the primary motor cortex, typically one 
electrode is placed on the scalp over M1 and the other over the contralateral 
supraorbital area. The duration and strength of the after-effects of tDCS usually 
depend on stimulation intensity and duration (Nitsche & Paulus, 2001; Nitsche et al., 
2003a). In addition to the motor cortex, tDCS can also be applied to visual and 
somatosensory systems, and has been shown to modulate cognitive processes, when 
applied over respective target regions (Kuo et al., 2014; Shin et al., 2015; Balzarotti & 
Colombo, 2016). TDCS protocols should state current strength, electrode size, 
stimulation duration, and electrode position to enhance comparability between studies 
(Nitsche et al., 2008). 
 
1.3 Pharmacological modulation of human cortical plasticity 
Neuromodulator systems (dopaminergic, cholinergic, serotoninergic and 
noradrenergic) have modulating roles on plasticity (Gu, 2002). Activation of these 
systems is not necessary to induce plasticity, but these systems have the capacity to 
modify the amount and direction of plasticity induced. Generally, the impact of 
neuromodulators depends on several factors such as the type of receptor subtypes, the 
dosage of the substance, and the cortical background activity in the specific brain 
region. Neuromodulators may impact on cortical plasticity through facilitation or 
reduction of NMDA receptor-gated processes, beyond other mechanisms (Gu, 2002). 
Serotonin and noradrenaline both play crucial roles in diverse brain functions and are 
also correlated with various neurological and psychiatric disorders (Normann et al., 
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2007; Marzo et al., 2009). Given the involvement of both transmitters in 
neuroplasticity, it is of great interest how pharmacological intervention will influence 
neurophysiologically induced plasticity. 
 
1.3.1 Serotonergic modulation of plasticity 
Serotonin (or 5-HT) is one of the most important neuromodulators in the central 
nervous system (Gu, 2002). It is also an important agent in diverse neuropsychiatric 
diseases such as depression. Serotonin has multiple receptor subtypes (5-HT1, 5-HT2, 
5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 receptors), which are linked to multiple 
signal transduction mechanisms and related to learning and memory formation in 
animals and humans (Geyer, 1996; Jacobs BL & Formal, 1997; Bert et al., 2008). One 
important foundation for its effects might be its impact on neuroplasticity (Gu, 2002). 
Animal experiments have shown that serotonin affects LTP and LTD in slice 
preparations. The direction of the effects depends on receptor subtypes, dosage of 
respective drugs, duration of 5-HT receptor activation, and site of action (Kojic et al., 
1997; Mori et al., 2001; Ohashi et al., 2003; Kemp & Manahan-Vaughan, 2005). In 
different studies, serotonin resulted in both LTP-enhancing and -abolishing effects 
(Kojic et al., 1997; Park et al., 2012). Regarding LTD, application of 5-HT agonists 
blocks LTD or even converts it into LTP, whereas 5-HT antagonists enhance LTD 
expression (Kemp & Manahan-Vaughan, 2005). These results confirm that serotonin 
is involved in brain plasticity, but the specific effects are complex.      
The effects of acute serotonin enhancement on motor cortical plasticity induced by 
tDCS and paired associative stimulation (PAS) were explored recently in healthy 
humans. In a foregoing study, a single dose of the selective serotonin receptor 
inhibitor (SSRI) citalopram enhanced both the amplitude and duration of the 
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after-effects of anodal tDCS until the same evening of stimulation, and it reversed the 
excitability diminution seen after cathodal tDCS into facilitation (Nitsche et al., 
2009). Likewise for PAS, acute application of citalopram enhanced PAS-induced 
LTP-like after-effects and abolished LTD-like PAS-induced after-effects (Batsikadze 
et al., 2013). These results show a prominent impact of serotonin on plasticity in 
humans. Similar effects were obtained for visual cortex plasticity (Normann et al., 
2007). These effects on plasticity might partially explain the positive effects of SSRI 
on motor task performance and memory formation in healthy individuals as well as on 
the recovery processes in rehabilitation therapy after stroke (Loubinoux et al., 2002; 
Loubinoux et al., 2005; Acler et al., 2009). 
 
1.3.2 Noradrenergic modulation of plasticity 
Noradrenaline is a crucial neuromodulator in the central nervous system which 
increases excitability and thus affects learning and memory processes in animals and 
humans (Wang et al., 2011; Robinson, 2012). Similar to serotonin, the precise effect 
of noradrenaline on plasticity, as explored in animal models, is complex and depends 
on receptor subtype, concentration, and the site of action (Marzo et al., 2009). 
Specifically, noradrenaline affects the direction of LTP as well as LTD dependent on 
the activation of α- and β-adrenoreceptors (Kemp & Manahan-Vaughan, 2008; Marzo 
et al., 2009). Pharmocological and receptor cloning studies have given rise to a further 
subdivision of this main grouping into α1 (divided into α1A, α1B, α1D), α2 (α2A, α2B, α2C, 
α2D), and β1, β2, β3receptor subtypes (Gu, 2002). In general, activation of 
β-adrenoreceptors enhances LTP, whereas the activation of α-adrenoreceptors reduces 
it (Marzo et al., 2009; Wojtowicz et al., 2010). For LTD, the effects of 
adrenoreceptors show conflicting results. With regard to β-adrenoreceptors, Kemp and 
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Mahahan-Vaughan described an enhancement of LTD, whereas LTD was abolished in 
another study (Katsuki et al., 1997; Kemp & Manahan-Vaughan, 2008). For 
α-adrenoreceptors, α2 receptor activation reduces LTD, while α1 receptors enhance it 
(Nakadate et al., 2006). The underlying mechanism of noradrenaline on 
neuroplasticity might be that activation of adrenoreceptors results in the activation of 
various intracellular factors and modifications of membrane ion channel opening 
(Nakadate et al., 2006; Marzo et al., 2009). β-adrenoreceptors activation decreases 
potassium conductance and results in depolarization of postsynaptic neurons (Hass & 
Konnerth, 1983). This results in enhancement of calcium currents into the 
intraneuronal compartment through NMDA receptors and voltage-dependent calcium 
channels, which is closely related to LTP induction (Heinbotham & Dunwiddie, 
1991). In contrast, α-adrenoreceptors induce neuronal membrane hyperpolarization by 
opening of potassium channels, which inhibits voltage activated calcium currents, and 
might be related to LTD expression (Kirwood et al., 1999). Furthermore, 
α-adrenoreceptors enhance GABA-induced inhibition in different cortical areas (Lei 
et al., 2007). 
With regard to noradrenergic modulation of human brain plasticity, a foregoing 
study has shown that a single dose of the monoamine reuptake inhibitor amphetamine 
enhances the duration of the aftereffects of anodal tDCS (Nitsche et al., 2004). 
Furthermore, in accordance with the above-mentioned experiments in animal models, 
both, the aftereffects induced by anodal and cathodal tDCS, were reduced by a 
β-adrenergic receptor blocker (Nitsche et al., 2004). Methylphenidate, a 
noradrenaline-dopamine reuptake inhibitor, had however no effect on PAS-induced 
LTP-like plasticity, while PAS-induced LTP-like plasticity was abolished by an α1 
receptor antagonist (Korchounov & Ziemann, 2011). Taken together, the results of 
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these studies suggest that the adrenergic system significantly impacts on plasticity in 
humans, which is in accordance with the results from animal studies (Marzo et al., 
2009).  
Growing evidence suggests that psychiatric diseases such as major depression are 
accompanied by compromised LTP, which can be re-installed by antidepressant 
treatment (Campell & Macqueen, 2004; Castren, 2004). Patients with major 
depression show reduced LTP-like plasticity, as compared with healthy controls 
(Normann et al., 2007), and application of antidepressant agents can increase LTP-like 
plasticity. It was furthermore recently shown that chronic administration of the 
selective noradrenaline reuptake inhibitor (NRI) reboxetine (RBX) restored spatial 
learning deficits and hippocampal synaptic plasticity in an animal model of 
depression (Bhagya et al., 2015). For studies in humans, acute administration of RBX 
improves cognition and motor performance in healthy and depressed subjects 
(Ferguson et al., 2003; Wang et al., 2009). In summary, selective NRI might at least 
partially exert their treatment effects by enhancing LTP-like plasticity in depression, 
and therefore improve learning and cognition. With regard to therapeutic application, 
apart from depression, RBX has been shown to improve maximum grip power and 
finger tapping frequency in stroke patients, which might also be caused by 
noradrenaline-dependent modulation of neuroplasticity (Wang et al., 2011). Thus, 
NRI might have a potential for clinical application in various neurological and 
psychiatric diseases accompanied by pathological alterations of plasticity. However, 
knowledge about the impact of noradrenergic enhancement on neuroplasticity in 
humans on plasticity is limited at present.  
 
1.4 Acute vs. chronic application  
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In clinical studies, it is well known that maximal effects of serotonergic and 
noradrenergic agents are obtained after weeks or even months of treatment 
(Bezchilbnyk-Butler et al., 2000; Kasper et al., 2000), suggesting that longer-term 
adaptive changes contribute to therapeutic efficacy. Animal studies suggest that both 
single and repeated treatments with SSRI can enhance synaptic efficacy, but only 
repeated treatments significantly facilitated the induction of LTP compared to placebo 
medication (Ohashi et al., 2002). Another difference was observed after acute and 
chronic administration of SSRIs: a down-regulation of the brain-derived neurotrophic 
factor (BDNF) gene expression after 4h (acute) and an up-regulation after 14 days 
(chronic) of application of the agent in the rat hippocampus (Coppell et al., 2003). 
Besides, chronic administration of the selective noradrenaline reuptake inhibitor 
(NRI) reboxetine results in a greater net increase of extracellular noradrenalin and 
dopamine compared to an acute dose (Page & Lucki, 2002). Another NRI, 
desipramine improved cognitive functions in both acutely and chronically treated rats 
(Lapiz et al., 2007). In an human functional magnetic resonance imaging (fMRI) 
study, chronic administration of selective serotonin reuptake inhibitor (SSRI) induced 
a significant hypoactivation of the primary sensorimotor cortex, but an 
hyperactivation after single dose treatment (Loubinoux et al., 2005). Furthermore, 
recent TMS studies have shown different modulation of the input-output curve (I-O 
curve) and intracortical facilitation (ICF) after chronic administration of SSRI 
compared to single dose application (Gerdelat-Mas et al., 2005). These results imply 
that cortical excitability might be modulated in different ways according to the 
duration of treatment. One candidate mechanism, which can however not explain all 
results, might be desensitization or downregulation of receptors. The specific 
interaction between dosage, plasticity and serotonergic/noradrenergic activity in the 
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human brain is so far not systematically explored. 
 
1.5 Aims of the study 
The purpose of this work is to investigate the impact of serotonergic and 
noradrenergic neuromodulation on human brain physiology, especially cortical 
excitability, and plasticity, in larger detail. According to the literature, acute 
administration of the SSRI citalopram enhances facilitatory plasticity. Based on the 
above-mentioned study results, it might be speculated that chronic effects of 
citalopram might differ physiologically and functionally. Moreover, we are interested 
in the underlying mechanisms, i.e., modulatory effects on glutamatergic plasticity, 
and on the plasticity of the serotonergic system itself. Therefore, in the first study, we 
explored the impact of chronic application of the citalopram on plasticity induced by 
tDCS in healthy humans. Likewise for noradrenlaine, studies showed that acute 
administration affected neuroplasticity in humans. However, knowledge about the 
chronic effect of noradrenaline on neuroplasticity in humans is still missing. Thus, for 
the second study, we investigated the acute and chronic effects of selective NRI 
reboxetine on neuroplasticity in healthy subjects. Beyond its impact on plasticity, 
recent studies have shown that noradrenaline impacts also on cortical excitability in 
humans. Nevertheless, most of the studies so far were conducted in a single dose 
design. It cannot be excluded that also for cortical excitability, acute and chronic 
effects of noradrenergic enhancement differ. Thus for the third study, we explored the 
acute and chronic effects of noradrenaline on cortical excitability in humans. The 
knowledge we aim to gain via these studies might further help to optimize the 




Chapter 2- Original articles and manuscripts 
  This chapter contains two published articles and one submitted manuscript. The 
first study focused on chronic effects of serotonin on neuroplasticity in healthy 
humans. The second and third study investigated acute and chronic noradrenergic 
effects on neuroplasticity as well as cortical excitability in healthy humans. 
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2.1 Chronic enhancement of serotonin facilitates excitatory transcranial direct 
current stimulation-induced neuroplasticity 
Neuroplasticity, which is the dynamic structural and functional reorganization of 
central nervous system, is the foundation of various cognitive, motor, and behavioral 
processes in humans. In the past decades, it became increasingly clear that 
pathological alteration of neuroplasticity is involved in various neuropsychiatric 
diseases. Therefore, modification of such pathological plasticity might be a promising 
therapeutic opportunity. Indeed, studies have found that distress disrupts 
neuroplasticity, while antidepressant treatment, including serotonin enhancement via 
selective serotonin reuptake inhibitor (SSRI), produces opposing effects in animal 
models and humans (Henn & Vollmayer, 2004; Normann et al., 2007). In a foregoing 
study, a single dose of the SSRI citalopram enhanced both the amplitude and duration 
of the after-effects of anodal transcranial direct current stimulation (tDCS) until the 
same evening of stimulation, and it reversed the excitability diminution seen after 
cathodal tDCS into facilitation (Nitsche et al., 2009). Likewise for paired associative 
stimulation (PAS), acute application of citalopram enhanced long term potentiation 
(LTP)-like PAS-induced after-effects and abolished long term depression (LTD)-like 
PAS-induced after-effects (Batsikadze et al., 2013). Therefore, SSRI treatment may 
exert a therapeutic effect via modulation of brain plasticity. Clinically it usually takes 
several weeks to obtain therapeutic effects via SSRI (Bezchilbnyk-Butler et al., 2000). 
Thus it can be speculated that the physiological effects of acute and chronic serotonin 
enhancement differ. However, the effect of chronic administration of SSRIs on 
neuroplasticity in humans has not yet been explored, and the underlying mechanism is 
unclear. Here we explored the impact of chronic SSRI citalopram application on 
tDCS-induced neuroplasticity in healthy humans in a randomized, double-blinded, 
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crossover design. The N-methyl-D-asparate (NMDA) receptor antagonist 
(dextromethorphan) was also applied to test the role of citalopram in modulating 
glutamatergic plasticity. 12 subjects received anodal or cathodal tDCS over the 
primary motor cortex combined with placebo medication. Afterwards, they took 
citalopram (20 mg/day) for 35 days, during which four additional plasticity induction 
sessions were applied (citalopram combined with dextromethorphan or placebo + 
anodal/ cathodal tDCS). Plasticity was monitored by motor evoked potentials with 
transcranial magnetic stimulation. Chronic application of citalopram increased and 
prolonged the LTP-like plasticity induced by anodal tDCS for over 24 hours, and 
converted cathodal tDCS-induced LTD-like plasticity into facilitation. These effects 
were abolished by the NMDA receptor antagonist dextromethorphan. Thus chronic 
serotonergic enhancement results in a strengthening of LTP-like glutamatergic 
plasticity, which might partially explain the therapeutic impact of SSRIs in depression 
































2.2 Acute and chronic effects of noradrenergic enhancement on transcranial 
direct current stimulation (tDCS)-induced neuroplasticity in humans 
  Similar to serotonine, noradrenaline is thought to act on plasticity in the nervous 
system, which furthermore affects cognition and motor learning (Kemp & 
Manahan-Vaughan, 2008; Marzo et al., 2009). Studies have shown that both, acute 
and chronic administration of the selective noradrenaline reuptake inhibitor (NRI) 
reboxetine (RBX) restored spatial learning deficits and hippocampal synaptic 
plasticity in an animal model of depression (Bhagya et al., 2015). In human studies, 
acute administration of RBX improves cognition and motor performance in healthy 
and depressed subjects (Ferguson et al., 2003; Wang et al., 2009). Thus NRI might 
have a potential for clinical application in various neurological and psychiatric 
diseases accompanied by pathological alterations of plasticity. A previous study has 
shown that a single dose of the monoamine reuptake inhibitor amphetamine enhances 
the duration of the aftereffects of anodal transcranial direct current stimulation (tDCS) 
(Nitsche et al., 2004). Furthermore, both the aftereffects induced by anodal and 
cathodal tDCS were reduced by a β-adrenergic receptor blocker (Nitsche et al., 2004). 
The results of this study suggest that the adrenergic system significantly impacts on 
plasticity in humans. In clinical applications, it usually takes several weeks to obtain 
therapeutic effects through selective NRI (Kasper et al., 2000). Thus it might be 
specifically relevant to learn about the impact of chronic noradrenergic activity 
enhancement on physiological processes. Interestingly, chronic administration of the 
selective serotonin reuptake inhibitor (SSRI) citalopram increased and prolonged 
tDCS-induced long term potentiation (LTP)-like plasticity in healthy subjects as 
compared to placebo in our previous study (Kuo et al., 2016). Since serotonin and 
noradrenaline are both neuromodulators and are effective for treating depression, they 
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might show some similar patterns to the same plasticity-induction protocol. 
Nevertheless, related studies regarding chronic effects of noradrenlaine on 
neuroplasticity in humans are rare. The aim of the study was thus to explore the 
impact of single dose and chronic administration of the NRI RBX, on plasticity 
induced by tDCS in healthy humans via a double-blinded, placebo-controlled, 
randomized crossover study. 16 healthy volunteers received placebo or single dose 
RBX (8mg) before anodal or cathodal tDCS of the primary motor cortex. Afterwards, 
the same subjects took RBX (8 mg/day) consecutively for 21 days. During this period, 
two additional interventions were performed (RBX with anodal or cathodal tDCS), to 
explore the impact of chronic RBX treatment on plasticity. Plasticity was monitored 
by motor evoked potential amplitudes elicited by transcranial magnetic stimulation. 
Chronic administration of RBX increased and prolonged the LTP-like plasticity 
induced by anodal tDCS for over 24 hours. It significantly converted cathodal 
tDCS-induced long term depression (LTD)-like plasticity into facilitation, as 
compared to the single dose condition, for 120 minutes after stimulation. The results 
show a prominent impact of noradrenaline receptor enhancement on plasticity of the 
human brain. Specifically, noradrenergic enhancement fosters the impact of brain 
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Key point summary 
1. Chronic administration of the selective noradrenaline reuptake inhibitor (NRI) 
reboxetine (RBX) increased and prolonged the long term potentiation (LTP)-like 
plasticity induced by anodal transcranial direct current stimulation (tDCS) for 
over 24 hours. 
2. Chronic administration of RBX converted cathodal tDCS-induced long term 
depression (LTD)-like plasticity into facilitation for 120 min. 
3. Chronic noradrenergic activity enhancement on plasticity of the human brain 
might partially explain the delayed therapeutic impact of selective NRIs in 



















Noradrenaline affects cognition and motor learning processes via its impact on 
long-term potentiation (LTP) and depression (LTD). We aimed to explore the impact 
of single dose and chronic administration of the selective noradrenaline reuptake 
inhibitor (NRI) reboxetine (RBX) on plasticity induced by transcranial direct current 
stimulation (tDCS) in healthy humans via a double-blinded, placebo-controlled, 
randomized crossover study. 16 healthy volunteers received placebo or single dose 
RBX (8mg) before anodal or cathodal tDCS of the primary motor cortex. Afterwards, 
the same subjects took RBX (8 mg/day) consecutively for 21 days. During this period, 
two additional interventions were performed (RBX with anodal or cathodal tDCS), to 
explore the impact of chronic RBX treatment on plasticity. Plasticity was monitored 
by motor evoked potential amplitudes elicited by transcranial magnetic stimulation. 
Chronic administration of RBX increased and prolonged the LTP-like plasticity 
induced by anodal tDCS for over 24 hours. Chronic RBX significantly converted 
cathodal tDCS-induced LTD-like plasticity into facilitation, as compared to the single 
dose condition, for 120 minutes after stimulation. The results show a prominent 
impact of chronic noradrenergic enhancement on plasticity of the human brain which 
might partially explain the delayed therapeutic impact of selective NRIs in depression 
and other neuropsychiatric diseases. 
 
Abbreviations list: LTP, long-term potentiation; LTD, long-term depression; NRI, 
noradrenaline reuptake inhibitor; PLC, placebo; RBX, reboxetine; tDCS, transcranial 







Noradrenaline affects learning and memory processes via modulating long-term 
potentiation (LTP) and depression (LTD) (Tully et al., 2007; Wallings et al., 2016). 
The precise effect of noradrenaline on plasticity, as explored in animal models, is 
complex and depends on receptor subtype, concentration, and the site of action 
(Marzo et al., 2009). Specifically, noradrenaline affects the direction of LTP as well as 
LTD. Its specific impact depends on the activation of α- and β-adrenoreceptors (Kemp 
& Manahan-Vaughan, 2008; Marzo et al., 2009). Activation of adrenoreceptors affects 
various intracellular factors and modifications of ion channel opening (Marzo et al., 
2009). Importantly, adrenoreceptors also impact on N-methyl-D-aspartate (NMDA) 
and gamma-aminobutyric acid (GABA) receptors, and therefore influence the 
direction of LTP and LTD (Lei et al., 2007). 
 
Noninvasive brain stimulation techniques such as transcranial direct current 
stimulation (tDCS) have been established to induce LTP- and LTD-like cortical 
excitability alterations in humans (Nitsche & Paulus, 2000). TDCS induces 
polarity-dependent plasticity via its primary subthreshold effects on resting membrane 
potentials (Purpura & McMurtry, 1965; Nitsche et al., 2007). Anodal stimulation 
elicits neural depolarization which enhances cortical excitability, whereas cathodal 
tDCS results in neural hyperpolarization which diminishes cortical excitability. 
Stimulation for some minutes results in respective neuroplastic effects, which depend 
on glutamatergic mechanisms and are calcium-dependent (Nitsche & Paulus, 2000, 
2001; Nitsche et al., 2003a; Nitsche at al., 2005). Nevertheless, tDCS-induced 
plasticity differs from classical plasticity induction protocols, used primarily in vitro. 
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The latter involve not tonic subthreshold, but pulsatile suprathreshold stimulation. 
Thus, mechanisms of plasticity might not be identical, although similarities like 
NMDA receptor dependency, and calcium dependency, are present (Liebtanz et al., 
2002; Nitsche et al., 2003b). A previous study has shown that acute administration of 
the monoamine reuptake inhibitor amphetamine enhances the duration of the 
aftereffects of anodal tDCS (Nitsche et al., 2004). Furthermore both, the aftereffects 
induced by anodal and cathodal tDCS, were reduced by a β-adrenergic receptor 
blocker (Nitsche et al., 2004). The results of this study suggest that the adrenergic 
system significantly impacts on plasticity in humans, which is in accordance with the 
results from animal studies (Nakadate et al., 2006; Marzo et al., 2009).  
 
Psychiatric diseases such as major depression are accompanied by compromised LTP, 
which can be restored by antidepressant treatment (Campell & Macqueen, 2004; 
Castren, 2004). Patients with major depression show reduced LTP-like plasticity, as 
compared with healthy controls, and administration of antidepressant agents can 
increase LTP-like plasticity (Normann et al., 2007). Furthermore, chronic 
administration of the selective noradrenaline reuptake inhibitor (NRI), reboxetine 
(RBX), restored spatial learning deficits and hippocampal synaptic plasticity in an 
animal model of depression (Bhagya et al., 2015). For studies in humans, acute 
administration of RBX improves cognition and motor performance in healthy and 
depressed subjects (Ferguson et al., 2003; Plewnia et al., 2004; Wang et al., 2009). In 
summary, selective NRIs might partially exert their treatment effects by enhancing 
LTP-like plasticity in depression, and therefore improve learning and cognition. Thus 
selective NRIs might have a potential for treatment of psychiatric diseases 
accompanied by pathological alterations of plasticity. Knowledge about the impact of 
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noradrenergic enhancement in humans on plasticity is however limited at present. 
Clinically, it usually takes weeks to obtain therapeutic effects through selective NRIs 
(Kasper et al., 2000), such it might be relevant to learn about the impact of chronic 
noradrenergic activity enhancement on physiological processes.  
 
Here, we explored the impact of single dose and chronic noradrenergic receptor 
activity enhancement via administration of the selective NRI RBX, on tDCS-induced 
motor cortical plasticity. We hypothesized that RBX increases LTP-like plasticity 
induced by anodal tDCS, whereas cathodal tDCS-induced LTD-like plasticity should 
be abolished or converted into excitation. Additionally, a foregoing study found that 
chronic administration of the selective serotonin reuptake inhibitor (SSRI) citalopram 
increased and prolonged tDCS-induced LTP-like plasticity in healthy subjects as 
compared to placebo (Kuo et al., 2016). This might indicate more stable serotonergic 
enhancement or upregulation of respective receptors due to chronic administration 
(Pariente et al., 2001; Coppell et al., 2003). Since serotonin and noradrenaline are 
both neuromodulators and are effective for treating depression, they might show some 
similar patterns to the same plasticity-induction protocol. We furthermore 
hypothesized that chronic administration of RBX should induce more prominent 
effects as compared to single dose administration. 
 
Material and Methods 
 
Ethical approval 
The study was approved by the ethics committee of the University Medical Center of 
Goettingen, and we conformed to the standards set by the Declaration of Helsinki 
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(2008 version). Written informed consent was obtained from all subjects who 
participated in the study before inclusion. 
 
Subjects 
Sixteen right-handed, healthy subjects participated in the experiments (8 males, age 
27.5±4.01 (standard deviation) years). Subjects were all right-handed, and between 18 
and 50 years old. They had no history of chronic or acute neurological, psychiatric, or 
medical diseases, no family history of epilepsy, no present pregnancy, no cardiac 
pacemaker, no previous surgery involving implants to the head (cochlear implants, 
aneurysm clips, brain electrodes), and absent acute or chronic medication or drug 
intake, including nicotine consumption. Participants familiar with non-invasive brain 
stimulation and pharmacological studies were preferred. However, responder or 
non-responder status (i.e., to tDCS) did not serve as criterion to include or exclude 
participants and we did not check for genetic polymorphisms (brain-derived 
neurotrophic factor (BDNF), catechol-O-methyl transferase (COMT), or others).  
 
Transcranial direct current stimulation  
Direct current was applied through a pair of saline-soaked surface sponge electrodes 
(35 m²) and delivered by a battery-driven constant current stimulator (neuroConn 
GmbH, Ilmenau, Germany) with a maximum output of 4.5 mA. The stimulating 
electrode was placed over the representational hotspot of the right abductor digiti 
minimi muscle (ADM) identified with transcranial magnetic stimulation (TMS), and 
the return electrode was placed contralaterally above the right orbit. A current strength 
of 1 mA was administered for 9 min for cathodal tDCS and 13 min for anodal tDCS. 
These stimulation durations induce cortical excitability alterations lasting 
 
37 
approximately for 1 hour after the end of stimulation (Nitsche & Paulus, 2001; 
Nitsche et al., 2003a). In our study, we aimed to keep the classical protocol identical 
to other pharmacology-tDCS studies in our lab to enhance comparability between 
studies (Kuoet al., 2008; Monte-Silva et al., 2010; Fresnoza et al., 2014 ). 
 
Pharmacological interventions 
Reboxetine (RBX) (8mg) (Winthrop Arzneimittel GmbH, Frankfurt am Main, 
Germany) or equivalent placebo medication (PLC) (Pfizer Italia S.r.l., Ascoli Piceno, 
Italy) was administered 2 hours before the start of the experimental sessions. A 
sufficient plasma level of RBX is achieved 2 hours after oral intake, and the 
respective dose is sufficient to elicit prominent effects in the central nervous system 
(Dostert et al., 1997). Steady state plasma concentrations are achieved after five days 
of drug intake (Pellizzoni et al., 1996). In clinical application, the majority of 
antidepressants have therapeutic effects after approximately two weeks of treatment 
(Dostert et al., 1997; Kasper et al., 2000). Therefore, we choose three weeks 
administration of RBX for the chronic part of experiments, and started plasticity 
induction procedures after 2 weeks of administration in the chronic medication 
condition. 
 
Monitoring of motor cortical excitability 
TMS-elicited motor evoked potentials (MEPs) were recorded to monitor excitability 
changes of the motor cortical representation of the right abductor digiti minimi 
muscle (ADM). Single-pulse TMS was conducted by a Magstim 200 magnetic 
stimulator (Magstim, Whiteland, Dyfed, UK) with a figure-of-eight magnetic coil 
(diameter of one winding=70 mm, peak magnetic field=2.2 T). The coil was held 
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tangentially to the skull, with the handle pointing backwards and laterally at an angle 
of 45 deg from midline, inducing a posterior-anterior current flow direction in the 
motor cortex. The optimal coil position (hotspot) was defined as the site where 
stimulation consistently resulted in the largest MEPs of the contralateral ADM. 
Surface EMG was recorded from the right ADM with Ag-AgCl electrodes in a 
belly-tendon montage. The signals were filtered (2Hz to 2kHz, sampling rate 5kHz), 
amplified, and then stored on computer via a power 1401 data acquisition interface 
(Cambridge Electronic Design, Cambridge, UK).  
 
Experimental procedures 
The study was conducted in a double-blinded, counter-balanced and 
placebo-controlled design. Each subject participated in six experimental sessions, 
including single dose RBX (the first 4 sessions) and chronic RBX (the last 2 
sessions), or the respective placebo medication. For the single dose part, subjects 
received PLC or RBX combined with anodal or cathodal tDCS. Each experimental 
session was separated by one week to avoid cumulative effects. In the chronic RBX 
part, participants received RBX (8mg/day) consecutively for 21 days. The two 
sessions under chronic RBX application (RBX with anodal/cathodal tDCS) were 
conducted in counterbalanced order at the end of the second and third weeks after the 
start of chronic drug intake. At the beginning of each session, subjects were seated in 
a comfortable chair with head and arm rest. First the hotspot of the right ADM was 
determined over the left primary motor cortex, and 20 MEPs were recorded with the 
TMS intensity eliciting averaged 1mV MEP as the first baseline. Two hours after 
administration of the medication, a second baseline was obtained with the same 
intensity as BL2 to assess a possible influence of the medication on cortical 
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excitability, and a third baseline was recorded if necessary (if BL2 MEP was outside 
the range of 80 to 120 % of BL1 MEP) with adjusted TMS intensity for ~1mV MEP 
amplitude. Afterwards, tDCS was performed between 12 am and 1 pm. Immediately 
after tDCS, 20 MEPs were recorded at the time points of 0, 5, 10, 15, 20, 25, 30, 60, 
90, and 120 min, and also the same evening (se: between 6 pm and 7 pm), next 
morning (nm: between 9 am and 10 am), next noon (nn: between 12 am and 1 pm), 
and next evening (ne: between 6 pm and 7 pm) (Figure 1). 
 
Statistics 
The individual MEP amplitude means of baseline 1, 2, 3, and all time points after 
stimulation were calculated. After checking for normal distribution (Shapiro-Wilk 
test), a repeated-measure analysis of variance (ANOVA) for the time bins up to next 
evening after stimulation was calculated with the within subject factors time course, 
drug condition (placebo medication, single dose RBX and chronic RBX), stimulation 
type (anodal and cathodal) and the dependent variable raw MEP amplitude, including 
baseline 2, or, in case of adjustment of MEP amplitudes, baseline 3. The Mauchly test 
of sphericity was conducted, and the Greenhouse-Geisser correction was applied 
when necessary. In case of significant results of the ANOVA, post hoc comparisons 
were performed using Student’s t tests (paired samples, two tailed, critical p<0.05, not 
corrected for multiple comparisons) to determine whether the MEP amplitudes before 
and after tDCS differed in each intervention condition and whether these differences 
depended on drug condition. Furthermore, we conducted an ANCOVA with baseline 
raw MEP (baseline 2, or, in case of adjustment of MEP amplitudes, baseline 3) as 
co-variate, and for the chronic medication condition with order as co-variate to rule 




To explore if baseline MEP, and TMS intensity (percentage of maximal stimulator 
output, %MSO) needed to obtain baseline MEP differed between each session, the 
respective baselines were compared via Student’s t-tests (paired samples, two tailed, 




All subjects tolerated tDCS and RBX well. None of them reported any side effects of 
either RBX or the stimulation upon request. RBX alone did not change baseline MEP 
amplitudes and stimulation intensity significantly, as revealed by Student’s t-tests 
comparing MEP between baseline 1 and baseline 2 (paired samples, two-tailed, 
p>0.05) (Table 1). 
 
The Shapiro-Wilk test indicted that all data were normally distributed (all p > 0.05). 
The results of the ANOVA showed significant main effects of drug (F(2)= 7.843; 
p=0.006), stimulation (F(1)= 19.852; p=0.002), and significant drug x stimulation 
(F(2)= 10.159; p=0.007), and stimulation x time (F(14)=4.964; p=0.005) interactions. 
In addition, the result of ANCOVA did not show a significant effect of baseline MEP 
(baseline 2, or, in case of adjustment of MEP amplitudes, baseline 3) (P=0.723), and 
the chronic medication conditions did not result in a significant effect of order (p = 
0.617) (Table 2).  
 
As revealed by the respective post hoc test, under placebo medication, cathodal tDCS 
decreased MEP amplitudes for up to 60 min after stimulation, whereas anodal tDCS 
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increased cortical excitability for 90 min. Single dose administration of RBX 
enhanced the MEP amplitudes significantly as compared to placebo medication at the 
time points of 10, 15, and 25 min after anodal tDCS, whereas it reversed cathodal 
tDCS-induced inhibition into facilitation, which remained significant for up to 60 min 
after tDCS. Under chronic RBX, anodal tDCS resulted in larger MEP amplitudes 
compared to placebo medication at the time point of 10, 15, 20, 25, 30, 60, 120, se, 
nm, nn, and ne after tDCS application. Furthermore, compared to the single dose 
condition, chronic RBX significantly increased MEP amplitudes at the time points of 
20, 25, 30, 60, 120, se, nm, nn, and ne, which means the MEP amplitude enhancement 
was present for more than 24 hours after tDCS until next evening after stimulation. 
For cathodal tDCS, chronic RBX showed a similar effect as single dose 
administration compared to the placebo condition, which converted inhibition into 
facilitation with a more prominent excitability enhancement for 120 minutes after 
stimulation. In addition, chronic RBX resulted in a significant enhancement of MEP 
amplitudes compared to the single dose condition for 30 minutes and at the time point 




The results of this study show that single dose administration of the selective NRI 
RBX increased LTP-like plasticity induced by anodal tDCS, whereas it turned 
cathodal tDCS-induced LTD-like plasticity into facilitation in healthy subjects. 
Moreover, under chronic administration, the LTP-like effects of anodal tDCS were 
prolonged for more than 24 hours after intervention, and thus lasted relatively longer 
than those under single dose administration or placebo medication. For cathodal 
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tDCS, chronic RBX showed larger LTP-like plasticity compared to single dose 
medication for 120 minutes after stimulation. The prolonged after-effects of anodal 
tDCS achieved by chronic RBX might explain the relevance of long-term 
administration of selective NRIs to exert optimal effects. Moreover, these findings 
support recent concepts that changes of neural plasticity are relevant for therapeutic 
effects of noradrenergic enhancement (Marzo et al., 2009; Bhagya et al., 2015).  
 
Baseline MEP showed no significant differences after RBX intake, which differs from 
another study (Plewnia et al., 2002; Plewnia et al., 2004). This difference between 
study results might be due to the fact that we used a stimulation intensity which elicits 
single pulse MEPs with peak-to-peak amplitudes on average 1 mV instead of 180% 
MT (motor threshold) in the foregoing one. The latter criterion will result in larger 
MEPs. The respective different effect of RBX on baseline MEP might be caused by 
different pharmacological mechanisms involved in low and high intensity parts of the 
recruitment curve. Thus high, but not low amplitude MEPs are relevantly affected by 
the glutamatergic system (Paulus et al., 2008). 
 
Mechanisms 
Our results are in accordance with the findings of a previous experiment, in which the 
monoamine reuptake inhibitor amphetamine prolonged the duration of the LTP-like 
after-effects induced by anodal tDCS (Nitsche et al., 2004). They are also in line with 
results of animal slice experiments. Noradrenergic enhancement can enhance LTP and 
block LTD (Katsuki et al., 1997; Tully et al., 2007). The specific mechanism 
responsible for the effects of RBX on motor cortex plasticity in the human brain 
remains to be clarified in future studies. One candidate mechanism is the decrease of 
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potassium conductance by the drug (Marzo et al., 2009). This would result in a 
depolarization of postsynaptic membranes and enhance calcium influx into the 
intraneuronal compartment through NMDA receptors and voltage-dependent calcium 
channels (Gu, 2002). The direction of induced plasticity depends on the amount of 
intracellular calcium. High enhancement of intracellular calcium induces LTP, 
whereas low enhancement results in LTD (Lisman, 2001). Since the after-effects of 
tDCS are NMDA receptor- and calcium-dependent (Liebtanz et al., 2002; Nitsche et 
al., 2003b), RBX might have strengthened the excitability enhancement induced by 
anodal tDCS through an enhancement of calcium influx, which might prolong the 
after effects of anodal tDCS. For cathodal tDCS, RBX might have shifted a small to 
large calcium increase through this mechanism and thus converted inhibition into 
facilitation. The calcium influx might be still lower for cathodal than for anodal tDCS, 
which would explain that the after effects of cathodal tDCS were shorter lasting. 
However, this suggested mechanism is speculative at present. Which specific 
noradrenaline receptor subtypes are involved in this mechanism is not clear. 
β-adrenoreceptors might be candidates, since in vivo and vitro studies conducted in 
the dentate gyrus and in area CA1 of the hippocampus show that noradrenaline 
facilitates or induces LTP through β-adrenoreceptors (Katsuki et al., 1997). 
Furthermore, since β-adrenoreceptors decrease calcium activation-dependent 
potassium conductance (Hass & Konnerth, 1983), they are relevant for the conversion 
from early to late LTP (Straube & Frey, 2003). Because noradrenaline also affects 
acetylcholine, serotonin, dopamine release and GABAergic activation (Page & Lucki, 
2002), which have been shown to modulate tDCS-induced plasticity, it cannot be 
ruled out that these modulators might have some impact on the effects (Kuo et al., 
2007; Kuo et al., 2008; Nitsche et al., 2009). Although the results of the present study 
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are rather clear, it should be kept in mind that in this study we explored a specific 
dosage of RBX, which is not selective for a specific noradrenergic receptor, and 
explored plasticity of a specific cortical area. The effects of activation of adrenergic 
receptor subtypes on LTP and LTD might however differ (Katsuki et al., 1997; Kemp 
& Manahan-Vaughan, 2008). Moreover, due to the neuromodulatory function of 
noradrenaline, noradrenergic activation might exert non-linear dosage-dependent 
effects, and specific effects might depend on receptor density of a specific area, which 
differ between regions (Katsuki et al., 1997; Marzo et al., 2009). These factors might 
explain at least partially conflicting results between studies. Future studies should 
thus consider the contribution of specific receptor subtypes, explore the impact of 
different dosages, and explore plasticity effects of noradrenaline in different cortical 
areas. These factors have been shown to contribute to the effects of other 
neuromodulators, such as dopamine, on plasticity (Kuo et al., 2008; Monte-Silva et 
al., 2010).    
 
Functional implications 
Previous studies have shown that acute administration of RBX improves cognitive 
and motor performance in healthy subjects and depressed patients (Ferguson et al., 
2003; Wang et al., 2009). Clinically, the majority of selective NRIs currently available 
has therapeutic effects only after approximately 2 weeks of treatment (Kasper et al., 
2000), suggesting that in addition to the rapid inhibition of noradrenaline reuptake, 
other long-term adaptive modifications are induced by chronic noradrenergic 
enhancement. Here, its impact on LTP-like plasticity is a candidate mechanism. 
Indeed, deficient LTP was restituted in patients suffering from major depression after 
successful therapy (Player et al., 2014). In our study, repeated treatment with RBX 
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significantly enhanced and prolonged LTP-like plasticity induced by anodal tDCS for 
more than 24h, suggesting induction of late phase LTP, whereas for single dose 
administration the after-effects of anodal tDCS were only extended until the evening 
of the day of intervention. In accordance, animal models of depression suggest that 
repeated treatment with selective NRIs significantly restores hippocampal synaptic 
plasticity and reduces spatial learning deficits (Marzo et al., 2009; Bhagya et al., 
2015). These findings indicate the possibility that the enhancement of synaptic 
plasticity may contribute to adaptive changes induced by long-term antidepressant 
treatment. Interestingly, we found similar effects for the SSRI citalopram (Kuo et al., 
2016). If this is a relevant mechanism, which can explain the delayed effects of 
antidepressants on clinical symptoms, remains to be shown directly. Beyond 
depression, compromised plasticity plays a role in various neurological and 
psychiatric diseases, and restitution by interventional approaches might be an 
important mechanism for reducing clinical symptoms. Noradrenergic enhancement 
might be relevant for diseases which are accompanied by deficient LTP, such as post 
stroke rehabilitation, and Parkinson´s disease, just to name a few. It was described 
that RBX can improve hand function in chronic stroke patients (Zittel et al., 2007). 
Moreover, tDCS has been introduced as a potential therapeutic tool for diverse 
neurological and psychiatric diseases (Flöel, 2014; Kuo et al., 2014). Given the 
strengthening effect of RBX on the aftereffects of tDCS, combining tDCS with 
selective NRIs might be a promising option to enhance the clinical impact of these 
interventions. Indeed, such synergistic effects have been demonstrated for the 





Some potential limitations of the present study should be considered. First, due to the 
limited time frame, we explored only three weeks for chronic administration of RBX. 
Second, to rule out an interference effects of plasticity interventions, a one week 
intersession interval was required. Since we did not have the chance to explore 
behavioral effects of noradrenaline in the present study, thus presumed functional 
implications are speculative at present. Third, we did not obtain drug plasma levels, 
which would have enabled exploration of dosage-dependent effects of the medication 
to some extent. Moreover, participants had not the exact identical duration of RBX 
intake in the respective chronic medication conditions (medication duration between 
14 and 21 days). Participants received anodal stimulation after two weeks and 
cathodal stimulation after three weeks of RBX, or vice versa. To rule out systematic 
effects of order of conditions on the results, we conducted an ANCOVA for the 
chronic medication condition with order as co-variate, which ruled out an order effect.  
 
Future studies 
Since animal experiments showed different effects of α and β receptors on plasticity 
(Kemp & Manahan-Vaughan, 2008; McElligott & Winder, 2008; Wojtowicz et al., 
2010), future studies should consider the contribution of specific receptor subtypes 
(i.e., α1, α2 and β1, β2, β3 subtypes) in more detail. Moreover, we have found a 
“focusing effect” of another neuromodulator, namely dopamine, on neuroplasticity, 
which strengthened focally induced but weakened/reversed nonfocally induced 
plasticity (Kuo et al., 2008; Fresnoza et al., 2014 ). In contrast, RBX might induce a 
de-focusing effect on plasticity, which would be an interesting difference to other 
neuromodulators. Therefore, future studies should consider to explore the 
noradrenergic effects with different plasticity induction protocols such as paired 
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associative stimulation (PAS), which induce more focally restricted plasticity. Given 
the variability of neuromodulatory brain stimulation interventions (López-Alonso et 
al., 2014; Wiethoff et al., 2014), replication of the results of this study is also 
warranted. Finally, the results of the study were obtained in healthy volunteers. In 
neuropsychiatric diseases, transmitter availability and other features of brain function 
might be different. Thus, the assessment of the current setup in patients groups 
suffering from depression, stroke and other neurological and psychiatric syndromes in 
which the adrenergic system or neuroplasticity are involved is required to explore 
transferability of results, and mechanisms.  
 
Our results show modulatory effects of the selective NRI, RBX, on tDCS-induced 
plasticity in the human motor cortex. RBX shifted tDCS-induced plasticity into a 
facilitatory direction. This impact of noradrenaline on plasticity may be a relevant 
neurological foundation for the therapeutic effect of selective NRIs in depressed 
subjects. This finding also suggests that long-term administration of selective NRIs 
might be a promising pathway to treat patients with neurological deficits associated 
with compromised LTP-like plasticity. Furthermore, the results may help to 
understand neuroplasticity processes in the human brain on the rational basis of 
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Drug Condition Baseline 1 Baseline 2 Baseline 3 p value 
Anodal MEP (mV) PLC 1.04 ± 0.12 0.98 ± 0.09 0.99 ± 0.06 0.396 
  Acute RBX 1.01 ± 0.03 0.95 ± 0.18 1.03 ± 0.16 0.153 
  Chronic RBX 1.04 ± 0.11 1.07 ± 0.08 1 ± 0.07 0.357 
 % MSO PLC 52 ± 8.07 52 ± 8.07 50.3 ± 6.74 0.178 
  Acute RBX 52.9 ± 7.11 52.9 ± 7.11 53.1 ± 7.56 0.445 
  Chronic RBX 52.1 ± 7.18 52.1 ± 7.18 51.4 ± 8.5 0.325 
Cathodal MEP (mV) PLC 1.03 ± 0.14 0.99 ± 0.12 1.01 ± 0.09 0.517 
  Acute RBX 1.01 ± 0.13 0.97 ± 0.09 0.99 ± 0.08 0.946 
  Chronic RBX 0.94 ± 0.06 1.03 ± 0.12 1 ± 0.09 0.063 
 % MSO PLC 52.9 ± 7.54 52.9 ± 7.54 53.3 ± 8.09 0.801 
  Acute RBX 51.6 ± 6.19 51.6 ± 6.19 51.3 ± 7.43 0.163 




Shown are the mean MEP amplitudes ± S.D. and stimulation intensity (percentage of 
maximum stimulator output, %MSO) mean ± S.D. of baseline 1, 2, and 3. The 
intensity of TMS was determined to elicit MEPs with a peak to peak amplitude of 
~1mV (baseline1). A second baseline (baseline 2) was recorded two hours after 
medication intake to determine the effect of the drug on cortical excitability and 
adjusted if necessary (baseline 3). Student’s t-tests revealed no significant differences 




Table 2. Results of the repeated-measures ANOVA. 
 
Parameters df F-value p-value 
Drug 2 7.843 0.006* 
Stimulation 1 19.852 0.002* 
Time 14 3.220 0.078 
Drug x Stimulation 2 10.159 0.007* 
Drug x Time 28 2.034 0.118 
Stimulation x Time 14 4.964 0.005* 























Figure 1. Experimental course of the present study.  
The study was conducted in two parts. For the single dose medication part, subjects 
received a single dosage of 8 mg reboxetine (RBX) or placebo medication (PLC) with 
anodal or cathodal tDCS. After these 4 sessions, which were separated by at least one 
week from each other, they took 8 mg RBX consecutively for 21 days. In the 
“chronic” part of the experiments, the other two sessions (RBX with anodal or 
cathodal tDCS) were conducted at the end of the second and third week. For each 
session, first baseline MEP (BL1) were recorded with TMS. Two hours after intake of 
the medication, a second baseline (BL2) was determined and adjusted if necessary 
(BL3). Afterwards, tDCS was applied and MEPs were recorded after stimulation at 













Figure 2. Impact of single dose and chronic reboxetine (RBX) on transcranial 
direct current stimulation (tDCS)-induced motor cortex plasticity. 
Shown are raw MEP amplitudes after plasticity induction by anodal/cathodal tDCS 
under placebo (PLC), single dose RBX (sRBX), or chronic RBX (cRBX) conditions 
up to the next evening of the stimulation day. (A) In the PLC condition (diamonds), 
anodal tDCS induced a significant excitability enhancement for up to 90 minutes after 
stimulation. Single dose RBX (square) resulted in excitability enhancements for up to 
120 minutes after stimulation. Chronic RBX (triangle) enhanced and prolonged these 
excitability enhancements until next evening. (B) In the PLC condition (diamond), 
cortical excitability was significantly reduced after cathodal tDCS for 60 minutes, 
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whereas single dose (square) and chronic RBX (triangle) converted the inhibitory 
effect into facilitation. Furthermore chronic RBX showed a significant enhancement 
of MEP amplitudes compared to the single dose condition for 30 minutes and at the 
time point of 90 after stimulation. Error bars indicate S.E.M. The black symbols 
indicate significant differences of post-stimulation MEP amplitudes 
fromrespectivebaseline values; Floating symbols (  : single dose RBX,  : chronic 
RBX) indicate a significant difference between respective RBX conditions and 
placebo medication at the same time points (Student’s t-test, two tailed, paired 
samples, p<0.05). *indicate significant differences between acute and chronic RBX 
conditions at the same time points (Student’s t-test, two tailed, paired samples, 


















2.3 Acute and chronic noradrenergic effects on cortical excitability in healthy 
humans  
Recent studies have shown that noradrenaline affects cortical excitability and 
cortical activity. A single dose of the selective noradrenaline reuptake inhibitor (NRI) 
reboxetine (RBX) enhanced the slope of input-output curve (I-O curve) and 
intracortical facilitation (ICF) but showed no effect on motor thresholds (MTs) and 
intracortical inhibition (Plewnia et al., 2002; Plewnia et al., 2004). In principal 
accordance, Herwig et al. reported increased ICF, but also decreased intracortical 
inhibition under RBX (Herwig et al., 2002). With regard to the contribution of 
adrenergic receptor subtypes, following a single dose of the α-2-adrenoreceptor 
agonist guanfacine, a decrease of the I-O curve and ICF as well as an increase of 
intracortical inhibition have been described (Korchounov et al., 2003). These findings 
confirm that noradrenaline is involved in human brain excitability, but the mechanism 
is complex, and probably receptor subtype-dependent. Clinically, therapeutic effects 
are usually obtained after some weeks (Kasper et al., 2000), which might go along 
with different physiological effects. However, the chronic impact of noradrenaline on 
cortical excitability has not been explored so far, and the underlying mechanism is 
also unclear. Therefore, the purpose of this study was to investigate the acute and 
chronic effects of the selective NRI RBX, on cortical excitability in healthy humans 
in a double-blind, placebo-controlled, randomized crossover study. Sixteen subjects 
were assessed with different TMS measurements: MTs, I-O curve, short-latency 
intracortical inhibition (SICI) and facilitation (ICF), I-wave facilitation, and 
short-interval afferent inhibition (SAI) before and after placebo or RBX (8mg) single 
dose administration. Afterwards, the same subjects took RBX (8mg/ day) 
consecutively for 21 days. During this period (subjects underwent two experimental 
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sessions with identical TMS measures under placebo or RBX medication), TMS 
measurements were assessed before and after drug intake. Both single dose and 
chronic administration of RBX increased the slope of the I-O curve, ICF, and I-wave 
facilitation, but decreased SICI and SAI. Moreover, chronic RBX showed a more 
stable enhancement of ICF and I-wave facilitation as compared to single dose 
application. The results might explain possible mechanisms underlying the beneficial 
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● Acute and chronic enhancement of noradrenergic brain activity via single dose 
and chronic administration of reboxetine (RBX) increases cortical excitability 
via enhancement of facilitation and reduction of inhibition. 
● Chronic RBX results in a more stable enhancement of intracortical facilitation 
and I-wave facilitation as compared to single dose application. 
● Chronic RBX itself, without an additional acute loading dose, enhances 















Background: Noradrenaline is a major neuromodulator in the central nervous system, 
and it is involved in the pathophysiology of diverse neuropsychiatric diseases. 
Previous transcranial magnetic stimulation (TMS) studies suggested that acute 
application of selective noradrenaline reuptake inhibitors (NRI) enhances cortical 
excitability in the human brain. However, it usually requires prolonged NRI treatment 
to achieve therapeutic effects in clinical populations, which might go along with 
different physiological effects.  
Methods: The purpose of this study was to investigate the acute and chronic effects 
of the selective NRI reboxetine (RBX) on cortical excitability in healthy humans in a 
double-blind, placebo-controlled, randomized crossover study. Sixteen subjects were 
assessed with different TMS measurements: motor thresholds (MTs), input-output 
curve (I-O curve), short-latency intracortical inhibition (SICI) and intracortical 
facilitation (ICF), I-wave facilitation, and short-interval afferent inhibition (SAI) 
before and after placebo or RBX (8mg) single dose administration. Afterwards, the 
same subjects took RBX (8mg/ day) consecutively for 21 days. During this period 
(subjects underwent two experimental sessions with identical TMS measures under 
placebo or RBX), TMS measurements were assessed before and after drug intake.
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Results: Both single dose and chronic administration of RBX increased cortical 
excitability, increased the slope of the I-O curve, ICF, and I-wave facilitation, but 
decreased SICI and SAI. Moreover, chronic RBX showed a more stable enhancement 
of ICF and I-wave facilitation as compared to single dose application.  
Conclusions: The results might explain possible mechanisms underlying the 
beneficial effect of RBX in neurological and psychiatric diseases.  
 
















Noradrenaline is a neuromodulator in the central nervous system (CNS) which 
regulates various neuropsychological processes (Bhagya et al., 2015; Robinson, 
2012). Moreover, a single dose of the selective noradrenaline reuptake inhibitor 
(NRI), reboxetine (RBX), can improve working memory and motor learning in 
healthy subjects as well as in clinical populations such as depression and stroke 
(Ferguson et al., 2003; Plewnia et al., 2004; Wang et al., 2009; Wang et al., 2011). 
The foundation for these effects might be the impact of noradrenaline on 
neuroplasticity and cortical excitability. Animal studies have shown that 
noradrenaline enhances long-term potentiation (LTP) as well as long-term depression 
(LTD) (Kirwood et al., 1999; Nakadate et al., 2006; Tully et al., 2007). The direction 
of LTP and LTD depends on the activation of α- and β-adrenoreceptors. Typically, 
activation of β-adrenoreceptors enhances LTP, whereas the activation of 
α-adrenoreceptors reduces it (Kemp and Manahan-Vaughan, 2008; Marzo et al., 
2009). These receptors also affect various intracellular processes such as ion channel 
opening via modulation of N-methyl-D-aspartate (NMDA) and gamma-aminobutyric 
acid (GABA) receptors (Hu et al., 2007; Tully et al., 2007). 
 
Recently, transcranial magnetic stimulation (TMS) measures have been applied to test 
the effects of noradrenaline on cortical excitability in humans. Corticospinal 
excitability can be assessed by active and resting motor thresholds (MTs) and the 
input-output curve (I-O curve) (Abbruzzese and Trompetto, 2002; Chen, 2000). MTs 
reflect neuronal membrane excitability and depend primarily on ion channel activity, 
as they are increased by voltage-gated sodium channel blockers, but not affected by 
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drugs modulating GABAergic or glutamatergic transmission (Ziemann et al., 1998a; 
Ziemann et al., 1996). The input-output curve (I-O curve) serves as an index of 
excitability of larger neuronal populations compared to MTs (Abbruzzese and 
Trompetto, 2002; Chen, 2000). The I-O curve depends on neuronal membrane 
excitability, because its slope is decreased by sodium and calcium channel blockers. 
Furthermore, synaptic mechanisms are involved as it is modulated by drugs 
influencing the GABAergic and glutamatergic system (Broojerdi et al., 1999; Lazzaro 
et al., 2003; Paulus et al., 2008). Short-latency intracortical inhibition (SICI) and 
intracortical facilitation (ICF), and motor cortex indirect waves (I-waves) are studied 
by paired-pulse TMS. SICI is mainly influenced by glutamate and GABAA receptors 
and based on the induction of inhibitory postsynaptic potentials (Liepert et al., 1997; 
Ziemann et al., 1998a; Ziemann et al., 1996). ICF is thought to reflect activity of 
GABAergic and glutamatergic systems. I-waves are thought to be primarily 
controlled by GABA-related neuronal circuits (Ziemann et al., 1998a; Ziemann et al., 
1998b). In previous studies, a single dose of RBX enhanced the slope of I-O curve 
and ICF but showed no effect on MTs and intracortical inhibition (Plewnia et al., 
2004; Plewnia et al., 2002). Herwig et al. also reported increased ICF, but also 
decreased intracortical inhibition under RBX (Herwig et al., 2002). With regard to the 
contribution of adrenergic receptor subtypes, following a single dose of the 
α-2-adrenoreceptor agonist guanfacine, a decrease of the I-O curve and ICF as well as 
an increase of intracortical inhibition have been described (Korchounov et al., 2003). 
Thus, the RBX-induced excitability enhancement, which differs relevantly from the 
effect of α-2-adrenoreceptor activation, might be primarily driven by excitatory 
effects of β-adrenoreceptors. These findings confirm that noradrenaline is involved in 
human brain excitability, but the mechanism is complex, and probably receptor 
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subtype-dependent. The above-mentioned pharmacological TMS studies were 
conducted via single dose protocols. In clinical applications, therapeutic effects are 
usually obtained after some weeks (Kasper et al., 2000). It might be speculated that 
the physiological effects of the respective substances differ between single dose and 
chronic treatment. Therefore, we aimed to compare the effects of single dose with 
chronic treatment of RBX on motor cortex excitability in healthy volunteers, using a 
variety of single and paired-pulse TMS measures tackling different ion channels and 
receptors. In accordance with previous studies, we hypothesized that a single dose of 
RBX enhances cortical excitability in healthy humans. According to the superior 
clinical results obtained from chronic treatment, we furthermore hypothesized that 
chronic application might also lead to more pronounced enhancement of cortical 





Sixteen healthy subjects (8 females) aged between 27.5±4.01 years (mean ± standard 
deviation) were recruited. Subjects were all right-handed, between 18 and 50 years 
old, and currently non-pregnant. None of them had a history of neurological diseases, 
electric implants in the body, or took other medications during the study period. 
Written informed consent was obtained from all subjects who participated in the study 
before inclusion. The study was approved by the Ethics Committee of the University 





8mg reboxetine (RBX) or an equivalent placebo (PLC) drug was administered 2 hours 
before the start of each experimental session, allowing the verum substance to induce 
a stable plasma level and prominent effects in the central nervous system (Dostert et 
al., 1997; Pellizzoni et al., 1996). Steady state plasma concentrations are achieved 
after five days of drug intake, and clinically, the majority of antidepressants have 
therapeutic effects after approximately 2 weeks of treatment (Dostert et al., 1997; 
Kasper et al., 2000). Thus, for the chronic RBX condition, we designated a three week 
period of RBX intervention, and started to measure cortical excitability after 2 weeks 
of application. 
 
Monitoring of motor cortical excitability 
Motor evoked potentials (MEPs) were induced in the right abductor digiti minimi 
muscle (ADM) by single-pulse TMS over the left primary motor cortex, conducted by 
a Magstim 200 magnetic stimulator (Magstim Company, Whiteland, Dyfed, United 
Kingdom) with a figure-of-eight magnetic coil (diameter of one winding=70mm; peak 
magnetic field=2.2 T). For the paired-pulse TMS protocols, the coil was connected to 
two Magstim 200 stimulators via a bistim module. The coil was held tangentially to 
the skull, with the handle pointing backwards and laterally at 45° from midline. The 
optimal position was defined as the site where TMS resulted consistently in the 
largest MEP. Surface electromyography (EMG) was recorded from the right ADM by 
use of Ag-AgCl electrodes in a belly tendon montage. The signals were amplified, 
and band-pass filtered (2Hz to 2 kHz; sampling rate, 5 kHz). Signals were digitized 
with a power 1401 data acquisition interface (Cambridge Electronic Design, 




Motor threshold determination 
The resting motor threshold (RMT) was defined as the minimum TMS intensity 
which elicited a peak-to-peak MEP of 50-100 μV in the relaxed muscle in at least 
three of six consecutive trials. The active motor threshold (AMT) was the minimum 
intensity eliciting a MEP response of ~200-300 μV during moderate spontaneous 
background muscle activity (~ 15% of the maximum muscle strength) in at least three 
of six consecutive trials.  
 
Input-output curve (I-O curve) 
The I-O curve was determined using TMS intensities of 100, 110, 130, and 150% 
RMT (15 stimuli per block (each intensity), with the order of the blocks randomized).  
 
Short-latency intracortical inhibition and intracortical facilitation (SICI-ICF) 
Short-latency intracortical inhibition and facilitation were measured by a TMS 
paired-pulse protocol including ISIs of 2, 3, 5, 10, and 15 ms. The first three ISIs 
represent inhibitory, and the last two ISIs reveal facilitatory effects, which reflect 
excitability of inhibitory and excitatory interneurons, respectively (Kujirai et al., 
1993). In this protocol, the subthreshold conditioning stimulus (determined as 70% of 
AMT) precedes the test stimulus. The test pulse was adjusted to achieve a baseline 
MEP of ~1mV and readjusted during the respective stimulation protocols, if needed, 
to compensate for effects of global excitability changes on test-pulse amplitude. The 
pairs of stimuli were organized in 15 blocks, where each ISI was represented once 






I-wave facilitation was investigated using a TMS paired-pulse protocol including ISIs 
of 1.1, 1.3, 1.5, 2.3, 2.5, 2.7, 2.9, 4.1, 4.3 and 4.5 ms (Ziemann et al., 1998b). In this 
protocol, the TMS test stimulus precedes the conditioning stimulus (determined as 
70% of RMT). The test pulse was adjusted to achieve a baseline MEP of ~1mV and 
readjusted during the respective stimulation protocols, if needed, to compensate for 
effects of global excitability changes on test-pulse amplitude. The pairs of stimuli 
were organized in blocks in which each ISI and one test pulse was represented once 
and was pseudo-randomized. These blocks were repeated 15 times.  
 
Short-interval afferent inhibition (SAI) 
SAI combines peripheral and motor cortex stimulation to evaluate activity of 
cholinergic systems in the human brain (Lazzaro et al., 2006). In this protocol, a 
suprathreshold electric pulse (width of 200 μs and an intensity of 200% of the 
perceptual threshold) over the ulnar nerve precedes the motor cortex TMS test pulse. 
The test pulse was adjusted to achieve a baseline MEP of ~1mV and readjusted 
during the respective stimulation protocols, if needed, to compensate for effects of 
global excitability changes on test-pulse amplitude. Peripheral nerve stimulation was 
delivered by a Digitimer D185 stimulator (Digitimer Ltd., Welwyn Garden City, 
United Kingdom). Interstimulus intervals of 20 and 40 ms between the peripheral and 
cortical stimulus were used (Lazzaro et al., 2006). The control-conditioning test pairs 
and a single TMS pulse control condition were recorded 20 times in random order.  
 
Experimental procedures 
The study was divided into two parts, each with two experimental sessions. Within 
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each part, sessions were carried out in randomized order and separated by at least one 
week to avoid cumulative drug effects. All volunteers completed both parts of the 
study. The first part explored single dose RBX effects. Subjects were seated in a 
comfortable chair with head and arm rests. The right ADM hotspot was determined 
over the left primary motor cortex, and 20 MEPs were recorded with the TMS 
intensity which elicited an average 1mV MEP (SI1mV). Afterwards, RMT and AMT 
were determined using standard procedures. After measuring AMT, a 15 min break 
followed to avoid a possible effect of muscle contraction on the next measurements. 
After this break, the following parameters were recorded in randomized order as 
baseline measures: I-O curve, SICI-ICF, I-wave facilitation and SAI. Afterwards, the 
participants took single-dose placebo (sPLC) or RBX (sRBX). Two hours after 
medication, TMS was readjusted to obtain single test pulse amplitudes of 1 mV, if 
needed. Then all of the above-mentioned parameters were measured again. The 
second part of the experiment explored chronic RBX effects. The same participants 
received RBX (8mg/day) consecutively for 21 days. During this period, the other two 
sessions with RBX (chronic RBX condition (cRBX): with RBX at the day of 
experiment) or placebo (chronic placebo condition (cPLC): with placebo at the day of 
experiment) were conducted in randomized order at the end of the second and third 
week after the start of chronic drug intake. The procedure in each session was the 




With regard to the RMT, AMT and SI1mV, the individual means of the TMS intensity 
at RMT, AMT and SI1mV were calculated for the before and after drug administration 
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conditions separately. Repeated-measures analyses of variance (ANOVA) were 
performed for the above-mentioned data using the RMT, AMT, and SI1mV value as the 
dependent variable, and drug condition (sPLC, sRBX, cRBX, and cPLC) and time 
point (pre- and post- medication) as independent within-subject factors. For 
significant ANOVA results, exploratory post hoc comparisons were performed using 
Student’s t-tests (paired samples, two tailed, p<0.05, not corrected for multiple 
comparisons). 
 
For the I-O curve, the individual means of MEP amplitudes were calculated for all 
subjects. Repeated-measures ANOVAs were performed on the above-mentioned data 
using MEP amplitudes as the dependent variable, and drug condition (sPLC, sRBX, 
cRBX, and cPLC), time point (pre- and post- medication), and TMS intensity as 
independent within-subject factors. For significant ANOVA results, exploratory post 
hoc comparisons were performed using Student’s t-tests (paired samples, two tailed, 
p<0.05, not corrected for multiple comparisons).  
 
Regarding SICI-ICF, I-wave facilitation, and SAI, the mean values were normalized 
to the respective single-pulse condition. First, intra-individual means were calculated 
for each condition. To determine significance, repeated measures ANOVAs were 
performed (ISIs, drug conditions, and time point as independent within-subject factors 
and MEP amplitude as the dependent variable). In case of significant results of the 
ANOVA, exploratory post hoc comparisons were performed using Student’s t-tests 






In follow-ups, all subjects tolerated TMS and RBX without side effects (one reported 
a mild tingling sensation during TMS, but did finish the whole session). For RMT, 
AMT, and SI1mV, the respective ANOVAs resulted in no significant main effects of 
drug and time or the respective interactions (all p>0.05) (Table 1). 
 
Input-output curve (I-O curve) 
As displayed in Table 1, the ANOVA showed significant main effects of drug 
(F(3)=4.916; p=0.006), intensity (F(3)=123.338; p<0.001) and drug x intensity 
interaction (F(9)= 4.869; P<0.001). This is due to enhanced MEP amplitudes caused 
by increased TMS stimulator output (100, 110, 130 and 150% RMT), and effects of 
different drug conditions on MEPs. As shown in Figure 2A, post hoc Student’s t-tests 
(paired, two-tailed, p<0.05) showed significantly larger MEP amplitudes elicited by 
110, 130, and 150% RMT TMS intensity in the sRBX_post compared to the 
sPLC_post condition. Application of chronic RBX showed significantly larger MEP 
amplitudes compared to the cPLC_post condition in the 110, 130, and 150% RMT 
TMS intensity (Figure 2B). Furthermore, cRBX_post significantly enhanced the MEP 
amplitude compared to the sRBX_post condition in the 110 and 150% RMT TMS 
conditions (Figure 2C). As compared to the sPLC_post condition, MEP amplitudes in 
the cPLC_post condition were significantly larger for 130 and 150% RMT, which 
reflects the long-lasting impact of chronic RBX application on cortical excitability 
(Figure 2D).  
 
Short-latency intracortical inhibition and intracortical facilitation (SICI-ICF) 
The ANOVA (Table 1) showed significant effects of drug (F(3)=8.423; P<0.001), 
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time (F(1)=9.489; P=0.01), ISI (F(4)=5.171; p=0.002), drug x time (F(3)=13.770; 
p<0.001), drug x ISI (F(12)=4.481; p<0.001), time x ISI (F(4)=5.831; p=0.001), and 
drug x time x ISI interaction (F(12)=5.267; p=0.001). Post hoc Student’s t-tests 
(paired, two-tailed, p<0.05) showed that both single dose and chronic RBX shifted 
cortical excitability towards an enhancement of excitability. As shown in Figure 3A, 
sRBX_post significantly increased facilitation at ISI of 15ms and decreased inhibition 
at ISIs of 2, 3 and 5 ms compared to the sPLC_post condition. Administration of 
chronic RBX resulted in significantly enhanced MEP amplitudes at ISIs of 2, 5, 10 
and 15ms compared to cPLC_post condition (Figure 3B). Moreover, a stronger 
facilitation at ISIs of 10, and 15 ms and decrease of inhibition at ISIs of 2 and 5 ms 
was observed under cRBX_post compared to sRBX_post (Figure 3C). As compared 
to the sPLC_post condition, the cPLC_post condition showed a non-significant trend 
torwards enhanced facilitation and decreased inhibition (Figure 3D).  
 
I-wave facilitation  
The ANOVA (Table 1) revealed significant effects of drug (F(3)= 3.254; p=0.034), 
ISI (F(9)=14.340; p<0.001), drug x ISI (F(27)=2.233; p<0.001), and drug x Time x 
ISI interaction (F(27)=1.767; p=0.012). The results are caused by significant 
enhancement of I-wave facilitation under both single dose and chronic RBX 
conditions. As shown in Figure 4A, application of single dose RBX significantly 
enhanced MEP amplitudes at all ISI compared sPLC_post condition. Similarly, 
cRBX_post significantly enhanced I-wave facilitation at nearly all ISIs compared to 
sPLC_post condition (Figure 4B). Administration of chronic RBX revealed a 
significantly enhanced facilitation at nearly all ISIs compared to the sRBX_post 
condition (Figure 4C). In addition, as compared to the sPLC_post condition, the 
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cPLC_post condition demonstrated significantly increased facilitation at all ISI 
(Figure 4D).  
 
Short-interval afferent inhibition (SAI) 
The ANOVA revealed significant main effects of drug (F(3)=19.886; p<0.001), time 
(F(1)= 14.218; p=0.003), and ISI (F(1)= 32.029; p<0.001) (Table 1). Accordingly, 
after application of single dose and chronic RBX, SAI was significantly decreased at 
ISI 20 ms. As compared to the sPLC condition, the cPLC condition demonstrated 
significant decreased SAI at ISI 20ms after drug intake. However, both, single dose 
and chronic RBX did not have any significant impact on SAI at an ISI of 40 ms 




In the present study, we explored the effects of single dose and chronic noradrenaline 
enhancement on cortical excitability in healthy subjects by different TMS protocols 
(corticospinal excitability: MTs and I-O curves; intracortical excitability: SICI-ICF, 
I-wave facilitation, and SAI). In general, our findings show enhanced corticospinal 
excitability, intracortical facilitation, and I-wave facilitation, but reduced intracortical 
inhibition and SAI after single dose and chronic RBX intake. Furthermore, 
intracortical facilitation and I-wave facilitation were more prominently enhanced in 
the chronic medication condition. These findings might partially explain why the 
onset of action of antidepressants takes several weeks in clinical application 
(Anderson et al., 2000; Heinbotham and Dunwiddie, 1991). Additionally, chronic 
RBX itself without an additional acute loading dose enhanced facilitation of I-O curve 
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and I-wave facilitation compared to placebo medication, which shows that chronic 
application of RBX itself results in prolonged excitability alteration.  
 
Regarding corticospinal excitability, AMT, RMT as well as SI1mV did not differ 
between single dose RBX, chronic RBX, and placebo medication. However, I-O 
curve MEP amplitudes were enhanced after both single dose and chronic RBX. 
Animal studies showing that noradrenaline enhances glutamatergic facilitation in the 
hippocampus might explain these results, as higher TMS intensities of the I-O curve 
are affected by glutamatergic mechanisms (Hu et al., 2007). Moreover, our results are 
in line with previous human studies which found that single dose RBX and the 
presynaptic α2-antagonist yohimbine increase the slope of I-O curve but do not alter 
MTs (Plewnia et al., 2001; Plewnia et al., 2004; Plewnia et al., 2002). Since 
measuring the I-O curve involves larger neuronal populations as compared to MTs, 
the sensitivity of the I-O curve in detecting cortical excitability changes might be 
superior. This - beyond the impact of glutamatergic mechanisms on the I-O curve - 
might be another reason why the I-O curves, but not MTs, are modulated by RBX. As 
the enhancement of the I-O curve originates at cortical or/and subcortical sites, our 
findings indicate that modulation of central noradrenaline is a possible way to 
enhance cortico-spinal excitability.  
 
SICI-ICF and I-wave facilitation were prominently modulated by RBX, especially in 
the chronic application mode. Here, we found enhanced ICF and I-wave facilitation as 
well as a decreased inhibition after RBX administration. ICF is regulated 
predominantly by glutamate receptors with some GABAA receptor contribution 
(Ziemann et al., 1998a; Ziemann et al., 1995; Ziemann et al., 1998b). SICI and I-wave 
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facilitation are suggested to be primarily controlled by GABAA receptors (Ilic et al., 
2002; Paulus et al., 2008; Ziemann et al., 1998b). Our results thus imply that 
noradrenaline exerts modulation effects on both, excitatory glutamatergic 
neurotransmission and GABA-related inhibition. These results are in accordance with 
those of former in-vivo and in-vitro studies showing that noradrenaline suppresses 
GABAergic inhibition and enhances glutamatergic facilitation (Hu et al., 2007; Tully 
et al., 2007). Furthermore, studies in humans have shown that single dose RBX 
decreases SICI and increases ICF (Herwig et al., 2002; Plewnia et al., 2004; Plewnia 
et al., 2002). These findings however contrast with one study, in which application of 
RBX for 16 days did not affect ICI and ICF (Lange and Liepert, 2007). A possible 
explanation might be the longer duration of drug intake in our study, which might 
result in more prominent effects.  
 
Since SAI is directly controlled by the cholinergic system, modulation of the 
noradrenergic system might have decreased SAI by cholinergic activation (Lazzaro et 
al., 2000). In the visual cortex, slice studies have shown that noradrenaline acts in 
combination with the cholinergic system, which results in facilitation of LTP 
(Brocher et al., 1992). However, a contribution of the GABAergic system to the RBX 
effects cannot be ruled out at present, as SAI is also affected by GABAergic 
mechanisms (Lazzaro et al., 2007), and other results of our study are in accordance 
with a prominent impact of RBX on GABA activity.  
 
Mechanisms 
The specific mechanisms responsible for the effects of RBX on cortical excitability in 
the human brain should be further investigated in forthcoming studies. One possible 
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mechanism is the reduction of potassium conductance by RBX (Hass and Konnerth, 
1983). This would result in a depolarization of postsynaptic membranes and enhance 
calcium influx into the intraneuronal compartment through NMDA receptors and 
voltage-dependent calcium channels, which might enhance cortical facilitation (Gu, 
2002). The β-adrenoreceptor might be the candidate involved in this mechanism as 
activation of β-adrenoreceptors decreases potassium conductance and results in 
depolarization of postsynaptic neurons (Hass and Konnerth, 1983). Moreover, the 
main mechanism suggested by the results of our experiments, an increase of 
glutamatergic and reduction of GABAergic activity by noradrenergic enhancement, is 
supported by recent animal studies showing that β-adrenoreceptors suppress 
GABAergic inhibition and facilitate activation of NMDA receptors in different brain 
areas (Hu et al., 2007; Tully et al., 2007).  
 
Functional relevance 
Our finding is in accordance with a previous study of our group in which it was 
shown that RBX prolongs and enhances LTP-like plasticity induced by non-invasive 
brain stimulation (unpublished observations). Additionally, recent studies have shown 
that increased excitability may be relevant for functional adaptation of neuronal 
networks in neuropsychiatric diseases (Henn and Vollmayer, 2004; Holderbach et al., 
2007; Nudo et al., 2001), which is in line with studies showing that noradrenergic 
agents improve cognitive processes such as working memory and motor learning in 
healthy and depressed subjects (Ferguson et al., 2003; Wang et al., 2011). Thus RBX 






Some potential limitations of the present study should be taken into account. First, the 
study was conducted in healthy subjects. In neuropsychiatric diseases, transmitter 
availability and other features of brain function might be different; future studies are 
thus needed to explore transferability of these results to patients. Moreover, the 
impact of noradrenaline on excitability based on dosages and receptor subtype 
contributions should be explored in future experiments. Finally, given the prominent 
effect of noradrenergic receptor activation on cortical excitability, future studies 
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Table 1. Repeated-measures ANOVA results  
 
Measurement Parameters df F-value p-value 
1-mV intensity Drug 3 0.358 0.784 
 Time 1 0.541 0.483 
 Drug x Time 3 1.583 0.220 
AMT Drug 3 2.663 0.071 
 Time 1 1.583 0.224 
 Drug x Time 3 1.254 0.112 
RMT Drug 3 0.534 0.663 
 Time 1 1.254 0.295 
 Drug x Time 3 0.544 0.486 
I-O curve Drug 3 4.916 0.006 
 Time 1 3.104 0.104 
 Intensity 3 123.338 <0.001 
 Drug x Time 3 1.762 0.174 
 Drug x Intensity 9 4.869 <0.001 
 Time x Intensity 3 1.230 0.314 
 Drug x Time x Intensity 9 1.159 0.330 
SICI-ICF Drug 3 8.423 <0.001 
 Time 1 9.489 0.01 
 ISI 4 5.171 0.002 
 Drug x Time 3 13.770 <0.001 
 Drug x ISI 12 4.481 <0.001 
 Time x ISI 4 5.831 0.001 
 Drug x Time x ISI 12 5.267 0.001 
I-wave facilitation Drug 3 3.254 0.034 
 Time 1 2.308 0.157 
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 ISI 9 14.340 <0.001 
 Drug x Time 3 1.820 0.163 
 Drug x ISI 27 2.233 <0.001 
 Time x ISI 9 0.863 0.561 
 Drug x Time x ISI 27 1.767 0.012 
SAI Drug 3 19.886 <0.001 
 Time 1 14.218 0.003 
 ISI 1 32.029 <0.001 
 Drug x Time 3 0.650 0.558 
 Drug x ISI 3 1.753 0.175 
 Time x ISI 1 1.497 0.247 




RMT=resting motor threshold; AMT=active motor threshold; I-O curve=input-output 
curve; SICI-ICF=short-latency intracortical inhibition and intracortical facilitation; 











Figure 1. Experimental course of the present study  
The study was conducted in two parts (single dose part and chronic part). For the 
single dose part, subjects received 8 mg single dose reboxetine (sRBX) or placebo 
medication (sPLC). First, transcranial magnetic stimulation (TMS) was applied over 
the left motor cortical representation area of the right abductor digiti minimi muscle 
(ADM) with an intensity to elicit motor-evoked potentials (MEPs) with a 
peak-to-peak amplitude of on average 1mV (SI1mV). Then, active and resting motor 
thresholds (AMT and RMT) were determined. Afterwards, input-output curve (I-O 
curve), short-latency intracortical inhibition and intracortical facilitation (SICI-ICF), 
I-wave facilitation and short-interval afferent inhibition (SAI) were conducted in 
randomized order. Two hours after intake of the medication, the same TMS 
measurements were repeated to explore the effect RBX on excitability. For the 
chronic part, the same subjects took 8 mg RBX consecutively for 21 days. During this 
period, the other two sessions (cRBX: with RBX at the day of experiment or cPLC: 
with PLC at the day of experiment) were conducted. The design of each session in the 










Figure 2. Input-output curve values before and after drug administration 
A-D displays the MEP amplitudes (means±SEM) at 100, 110, 130 and 150% of 
resting motor threshold (RMT) under four conditions: single dose placebo (sPLC), 
single dose reboxetine (sRBX), chronic reboxetine+placebo medication at the day of 
experiment (cPLC), and chronic reboxetine+reboxetine at the day of experiment 
(cRBX). A: sRBX_post showed significantly larger MEP amplitudes compared to 
sPLC_post elicited by 110, 130, and 150% RMT TMS. B: cRBX_post showed 
significantly larger MEP amplitudes compared to cPLC_post at 110, 130 and 150% 
RMT TMS. C: cRBX_post significantly enhanced the MEP amplitude compared to 
sRBX_post at 110 and 150% RMT TMS. D: cPLC_post showed significantly 
enhanced MEP compared to sPLC_post at 130 and 150% RMT TMS. Asterisks 
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indicate significant differences (Student’s t-test, P<0.05). Vertical bars depict 





















Figure 3. Short-latency intracortical inhibition and intracortical facilitation 
before and after drug administration 
Single-pulse standardized double stimulation MEP amplitude ratios±SEM are 
depicted for ISIs revealing inhibitory (ISIs of 2, 3 and 5 ms) and facilitatory (ISIs of 
10 and 15 ms) effects for different medication conditions: single dose placebo (sPLC), 
single dose RBX (sRBX), chronic reboxetine+placebo medication at the day of 
experiment (cPLC), and chronic reboxetine+reboxetine at the day of experiment 
(cRBX). A: The sRBX_post condition significantly increased facilitation for the ISI 
of 15 ms and decreased inhibition for ISIs of 2, 3 and 5 ms compared to sPLC_post 
condition. B: cRBX_post showed a significant increase of facilitation for the ISIs of  
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10 and 15 ms and a significant decrease of inhibition for the ISI of 3 and 5 ms 
compared to cPLC_post. C: cRBX_post showed significant facilitation for the ISIs of 
10, and 15 ms and significant decrease of inhibition for the ISIs of 2 and 5 ms 
compared sRBX_post. D: cPLC_post showed a non-significant trend torwards 
enhanced facilitation and decreased inhibition compared to sPLC_post. Asterisks 
indicate significant differences (Student’s t-test, P<0.05). Vertical bars depict 

















Figure 4. I-wave facilitation before and after drug administration 
Single-pulse standardized double stimulation MEP amplitude ratios±SEM are 
depicted for ISIs of 1.1, 1.3, 1.5, 2.3, 2.5, 2.7, 2.9, 4.1, 4.3 and 4.5 ms with different 
conditions: single does placebo (sPLC), single dose reboxetine (sRBX), chronic 
reboxetine + placebo medication at the day of experiment (cPLC), and chronic 
reboxetine + reboxetine at the day of experiment (cRBX). A: sRBX_post significantly 
enhanced MEP amplitude at all ISIs compare to sPLC_post. B: cRBX_post 
significantly enhanced I-wave facilitation at most ISIs compared to cPLC_post. C: 
cRBX_post revealed a significant enhancement of facilitation at most ISIs compared 
to sRBX_post. D: cPLC_post demonstrated significantly increased facilitation at all 
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ISIs compared to sPLC_post. Asterisks indicate significant differences (Student’s 



















Figure 5. Short-interval afferent inhibition before and after drug administration 
The figure displays SAI under different conditions: single dose placebo (sPLC), 
single dose reboxetine (RBX), chronic reboxetine+placebo medication at the day of 
experiment (cPLC), and chronic reboxetine+reboxetine at the day of experiment 
(cRBX). After application of both, single dose and chronic reboxetine, SAI was 
significantly decreased for ISI 20. As compared to the sPLC condition, in the cPLC 
condition, SAI was significantly reduced at ISI 20ms. Asterisks indicate significant 
differences of the MEP amplitude between before and after drug intake (Student’s 
t-test, P<0.05).  The Hash symbol indicates significant differences of the MEP 
amplitude between sPLC and cPLC after drug intake. Vertical bars depict standard 








Chapter 3- Summary 
 
3.1 General remarks 
The studies included in the thesis explored the impact of the neuromodulators 
serotonin and noradrenaline on human brain physiology relevant for cognition and 
behavior, namely cortical excitability and plasticity. In the first study, our results 
showed that chronic activation of serotonergic systems enhanced and prolonged 
facilitatory plasticity, whereas it converted inhibitory plasticity into facilitation. In 
addition, serotonin modulated N-methyl-D-asparate (NMDA) receptor-dependent 
plasticity, but did not induce plasticity by itself. In the second study, both acute and 
chronic noradrenergic activation enhanced facilitatory plasticity, whereas it converted 
inhibitory plasticity into facilitation, but chronic application showed more stable 
effects. In the third study, acute and chronic enhancement of the noradrenergic system 
increased cortical excitability via enhancement of facilitation and reduction of 
inhibition. Furthermore, the chronic medication condition resulted in a more stable 
cortical excitability enhancement as compared to single dose application. These 
findings add important information to our understanding of the mechanisms of 
consolidation of neuroplasticity and excitability in the human cortex.  
 
3.2 Functional implications 
Our findings confirm that serotonin and noradrenaline impact on plasticity and 
excitability of the human brain. In the field of clinical application, the results might 
imply that serotonergic and noradrenergic agents have therapeutic effects by 
enhancing facilitatory plasticity and increasing cortical excitability. Moreover, since 
chronic administration showed more stable results, this might partially explain why 
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the maximal effects of antidepressant agents are usually obtained after prolonged 
treatment periods. 
Recently, transcranial direct current stimulation (tDCS) is increasingly applied for 
treatment of neurological and psychiatric diseases (Kuo et al., 2014). In many cases, it 
is used to induce facilitatory plasticity for therapeutic effects. Given the strengthening 
effect of citalopram and reboxetine on the after-effects of tDCS, combining tDCS 
with pharmacological agents might be a promising venue to enhance its clinical 
impact. In accordance, it was shown recently that combined tDCS and selective 
serotonin reuptake inhibitor (SSRI) treatment had a superior impact on major 
depression, compared both of the interventions alone or placebo treatment (Brunoni et 
al., 2013). Likewise, SSRIs and selective noradrenaline reuptake inhibitors (NRI) 
might be suited to strengthen tDCS effects in other diseases such as Alzheimer’s 
disease, Parkinson’s disease, or motor rehabilitation after stroke. Future studies should 
explore these possibilities and include functional outcomes to assess the agonistic 
effects of brain stimulation and SSRI/selective NRI therapy. 
 
3.3 Limitations 
Some potential limitations of the present work should be taken into account. First, 
we did not obtain drug plasma levels, which would have enabled exploration of 
dosage-dependent effects of the medication to some extent. Moreover, all studies in 
the thesis were conducted in healthy subjects. In neuropsychiatric diseases, 
transmitter availability and other features of brain function might be different. Finally, 
due to the limited time frame, we did not have the chance to explore the behavioral 
effects of serotonin and noradrenaline in these studies, thus presumed functional 




3.4 Future perspectives 
Our studies explored the impact of serotonergic activation on neuroplasticity and 
noradrenergic activation on plasticity as well as on cortical excitability in humans. 
The results supply clear evidence for the relevance of these receptors with regard to 
respective physiological processes. Future studies should explore the mechanisms of 
action of these effects in larger detail, regarding dosages, receptor subtypes, and 
different plasticity induction techniques. Apart from experiments in humans, cellular, 
slice and in vivo animal experiments are essential, and will help to understand the 
mechanisms of action of both neuromodulators on plasticity and excitability into 
larger detail, because they enable the exploration of biological effects on a level not 
accessible for experiments in humans. 
Pathologically altered plasticity, especially compromised LTP, recently came into 
the focus of attention as a potentially important pathophysiological mechanism in 
various neurological and psychiatric diseases, e.g., major depression, Alzheimer´s 
disease, Parkinson’s disease, and others. However, our study was conducted in 
healthy young humans. A one-to-one transferability of the results to participants with 
other characteristics cannot be taken for granted, because the basal state of brain 
activity and excitability will differ between groups, which might relevantly affect 
intervention effects. For future studies, it will be interesting to explore if therapeutic 
medication in these patients improves symptoms at least partly due to a 
re-establishment of plasticity or pathologically altered excitability. 
Beyond tDCS, a variety of stimulation methods with different plasticity 
mechanisms is available that can be used to evaluate the effects of neuromodulatory 
systems on plasticity in humans. For example, PAS shows more focal effects 
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compared to tDCS. Furthermore, similar to other neuromodulators such as dopamine, 
the effects of SSRI and selective NRI might be specific for the kind of plasticity 
induction (Kuo et al., 2008; Fresnoza et al., 2014 ). Exploration of the intervention on 
different cortical areas could also be interesting in the future, since effects might 
differ due to area-specific receptor subtype composition. Specifically, plasticity 
induction of the dorsolateral prefrontal cortex with tDCS could be relevant for our 
understanding of the pathophysiological foundation of depression (Rajji et al., 2013), 
because this cortical area is closer related to respective symptoms of the disease as 
compared with the primary motor cortex, which we investigated in our present study. 
Neuroplasticity and cortical excitability are thought to be important foundations for 
cognition and motor learning. Serotonergic and noradrenergic agents have been 
shown to improve cognition and motor behavior in healthy humans and patients 
suffering from neurological and psychiatric disorders (Loubinoux et al., 2002; 
Ferguson et al., 2003). In addition, for acute and chronic administration of the drug, 
this functional improvement was accompanied by enhanced cortical excitability and 
also facilitatory plasticity (Pariente et al., 2001; Loubinoux et al., 2002). It is 
important to investigate further if alterations of plasticity and cortical excitability 
induced by serotonergic and noradrenergic agents are related to the respective 
cognitive effects and functional outcomes. Future studies will explore the association 
between neuroplasticity, cortical excitability, cognitive performance, and functional 
outcome in larger detail.           
Overall, improved knowledge about the mechanisms of neuroplasticity and 
excitability of the human brain will strengthen the possibility to shape the plastic 
potential of the brain, and might open a broader field of new therapeutic and research 
perspectives. However, we are still at the beginning of our understanding of the 
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neurophysiological and functional effects of neuromodulators on the human central 
nervous system. The central involvement of these substances in various brain 
functions in health and disease makes related studies important for improving our 
understanding of brain functions, but also for development of new therapeutic 
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